

A Method for Screening Cancer

BACKGROUND OF THE INVENTION

5 1. FIELD OF THE INVENTION

The invention relates to the cancer screening method, cancer screening biomarker, and use thereof. In particular, to the cancer screening method using methylated DNA as the biomarker.

10 2. DESCRIPTION OF THE PRIOR ART

Cervical cancer has been one of the main causes of death in females worldwide and in Taiwan. Based on the statistical survey by the World Health Organization (WHO) in 2002, cervical cancer was the second major disease responsible for the death of women
15 worldwide, second to breast cancer. Regular cervical cancer screening is the best way to prevent cervical cancer. Conventional cervical cancer screening includes two approaches: the most commonly used Pap smear, and human papilloma virus testing (HPV testing). Pap smear consists of sampling secreta from cervix uteri, examining under
20 microscope whether there is cancerous pathological change in the exfoliated epithelial cell, so as to detect cervical cancer early. On the other hand, HPV testing consists of examining whether human papilloma virus (HPV) is present in the specimen by using polymerase chain reaction (PCR) or Hybrid Capture.

25 There are, however, many undesired properties of Pap smear. For one, it requires sampling by a physician, and analysis by a medical

examiner/pathologist, which is a high cost of manpower that poses difficulty on promoting the test in many developing countries. Also, Pap smear has a high false negative rate which delays diagnosis and proper treatment prior to cancerous pathological change. As for HPV testing, although it is highly sensitive, it tends to create a high false positive rate, which not only leaves patients worry in vain, but also wastes much medical resources in examinations follow up to those false positive patients. Accordingly, one of the important topics in promoting cervical cancer examination relies on increasing the accuracy and convenience of cervical cancer examination method.

Genomic deletions have long been considered to be an important factor in tumorigenesis. For a long time, we have been accustomed to the idea that the coding potential of the genome lies within the arrangement of the four A, T, G, C bases. The two-hit theory proposed as early as in 1970s indicates concomitant mutations or deletions of some homologous tumor suppressor genes may cause or predispose to cancer development. However, additional information that affects phenotype can be stored in the modified base 5-methylcytosine. 5-Methylcytosine is found in mammals in the context of the palindromic sequence 5'-CpG-3'. Most CpG dinucleotide pairs are methylated in mammalian cells except some areas called "CpG island." CpG islands are GC- and CpG-rich areas of approximately 1 kb, usually located in the vicinity of genes and often found near the promoter of widely expressed genes. Cytosine methylation occurs after DNA synthesis, by enzymatic transfer of a methyl group from the methyl donor *S*-adenosylmethionine to the carbon-5 position of cytosine. The enzymatic reaction is performed by DNA

5 methyltransferases (DNMTs). DNMT1 is the main methyltransferase in mammals, and is responsible for the post-replicative restoration of hemi-methylated sites to full methylation, referred to as maintenance methylation, whereas DNMT3A and DNMT3B are thought to be involved primarily in methylating new sites, a process called *isolated* methylation.

10 Loss of methylation at CpG dinucleotides, i.e., general hypomethylation, was the first epigenetic abnormalities identified in cancer cells. However, during the past few years, it has become increasing apparent that site-specific hypermethylation, e.g., some tumor suppressor genes, is associated with loss of function which may provide selective advantages during carcinogenesis. Dense methylation of CpG islands at promoter regions can trigger chromatin remodeling through histone modifications with subsequent gene silencing. Therefore, in addition to chromosomal deletions or genetic mutations, epigenetic silencing of tumor suppressor genes by promoter hypermethylation is commonly seen in human cancer.

20 Epidemiologic studies have recently shown the correlation of serum folate level, a major source of methyl group, with the infection and clearance of HPV. Genetic polymorphisms of enzymes in the metabolism of methyl cycle were also reported to be associated with the development of cervical intraepithelial lesions. As the concept of epigenetics evolves, studies exploring the association between DNA methylation and cervical cancer are also booming. Studies of DNA methylation in cervical cancer are accumulating, which showed the potential of using methylation as markers in cervical screening. With the nature of the interface between genetics and environment, the

prevalence of methylation in tumor suppressor genes varies in different genes and different populations. The concept of methylator phenotypes with different disease behaviors was proposed with controversy. The methylator phenotype of cervical cancer and its
5 interaction with HPV genotypes still remains unknown. What genes are specifically methylated in cervical cancer and how many genes are required to achieve clinical application will remain a blossoming issue in the coming future.

The inventor of this application had filed relative patent
10 applications in Taiwan (TW Pat. Pub. No. 200831900) 、China(CN Appl. No. 200810094659.2) 、Malaysia(UI20085354) and America (US Pat. Pub. No. 20080311570) (Hereinafter referred as prior applications). Comparing with prior applications, the inventor had found some novel cancer screening biomarker and cancer screening
15 method using the same.

SUMMARY OF THE INVENTION

One object of the invention is to provide a cervical cancer screening method as the first line cervical cancer screening.

20 Another object of the invention is to provide a cervical cancer screening method, characterized in that said method can be used not only in the first line cervical cancer screening, but also in the second line cervical cancer screening to assist HPV testing or uncertain smear result in order to achieve more accurate cervical cancer screening
25 effect.

Yet another object of the invention is to provide a cancer screening method, characterized in that said method can be used in the

screening of cervical cancer as well as in the screening of other cancer (for example: ovarian cancer, colon cancer and the like) to assist the diagnosis of abnormal specimen.

Another object of the invention is to provide the cancer screening
5 biomarker, or a kit containing said biomarker to screen the risk of having cancer. The cancer screening method that can achieve the above-mentioned objects of the invention comprises of detecting the methylation rate of the target gene (biomarker) of the test specimen and use the testing result as a screening index to indicate the risk of
10 having cancer, and said method comprises following steps:

step 1: providing a isolated test specimen;

step 2: detecting the methylation rate of CpG sequence in at least one target gene within the genomic DNA of said test specimen, wherein said target gene comprising
15 DBC1, PDE8B, PTPRR and ZNF582; and

step 3: determining whether there is cancer or pre-cancerous pathological change or not in the specimen based on the methylation rate in the target gene, or using said methylation rate of target gene as prognosis marker;

20 wherein said test specimen comprising a cervical scraping, a ovarian cancer tissue, ascites, blood, urine, feces, sputum, oral mucous membrane cell, gastric juices, bile, cervical epithelial cell, and post-surgery cancer tissue;

wherein testing methods for the methylation state of CpG
25 sequence in said target gene comprising methylation-specific

polymerase chain reaction (MSP), quantitative methylation-specific polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high-performance liquid chromatography (DHPLC);

5 wherein the target gene DBC1 has the nucleotide sequence as depicted in SEQ ID No: 1;

 wherein the target gene PDE8B has the nucleotide sequence as depicted in SEQ ID No: 2;

 wherein the target gene PTPRR has the nucleotide sequence as
10 depicted in SEQ ID No: 3; and

 wherein the target gene ZNF582 has the nucleotide sequence as depicted in SEQ ID No: 4.

 In addition, the above-described screening index and screening method can be used further in the screening of cervical cancer, and
15 colon cancer.

 The invention provides further a ovarian cancer screening method, characterized in that said method tests the methylation state of the target gene of test specimen, and uses said methylation state as a screening index to determine the risk of having ovarian cancer, and
20 said method comprises following steps:

 step 1: providing a isolated test specimen;

 step 2: detecting the methylation rate of CpG sequence in at least one target gene within the genomic DNA of said test specimen, wherein said target gene comprising
25 DBC1, PTPRR and ZNF582; and,

step 3: determining whether there is ovarian cancer or cancerous pathological change or not in the specimen based on the methylation rate in the target gene, or using said methylation rate of target gene as prognosis marker;

5 wherein said test specimen comprising ovarian cancer tissue, ascites, blood, urine, and post-surgery cancer tissue;

wherein testing methods for the methylation state of CpG sequence in said target gene comprising methylation-specific polymerase chain reaction (MSP), quantitative methylation-specific

10 polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.

wherein the target gene DBC1 has the nucleotide sequence as depicted in SEQ ID No: 1;

15 wherein the target gene PTPRR has the nucleotide sequence as depicted in SEQ ID No: 3; and

wherein the target gene ZNF582 has the nucleotide sequence as depicted in SEQ ID No: 4.

Term “test specimen” refers herein to isolated test specimen, and

20 said isolated test specimen comprising the above-described cervical scraping, ascites, blood, urine, feces, sputum, oral mucous membrane cell, gastric juices, bile, cervical epithelial cell, post-surgery cancer tissue, or other suitable specimen. The inventive cancer screening method is useful to test the methylation state of target genes in said

25 isolated test specimens, and uses said methylation state of biomarker as a screening index of various types of cancer. The cancer screening

method and the screening index of biomarker provided by the invention can be employed by the researcher to perform the test in the laboratory.

Wherein, “the risk of having cancer” refers herein to the percentage of being cancer, the risk of getting cancer in future, or the presence or not of cancer.

Wherein when the methylation state of target gene (biomarker) being higher compare with suitable control, the risk of having cancer would be higher.

According said screening method, the invention provides further the cancer screening biomarker or a kit containg said biomarker to screen the methylation state of target gene (biomarker) in isolated test specimen for determining the risk of having cancer.

These features and advantages of the present invention will be fully understood and appreciated from the following detailed description of the accompanying Drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows the result obtained by performing bisulfite sequencing (BS) analysis on various cervical specimens using a target gene PTPRR in the inventive cancer screening method;

Figure 1B shows the result obtained by performing bisulfite sequencing (BS) analysis on various cervical specimens using a target gene ZNF582 in the inventive cancer screening method;

Figure 1C shows the result obtained by performing bisulfite sequencing (BS) analysis on various cervical specimens using a target

gene PDE8B in the inventive cancer screening method; and

Figure 1D shows the result obtained by performing bisulfite sequencing (BS) analysis on various cervical specimens using a target gene DBC1 in the inventive cancer screening method.

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention will be illustrated more detailed with the following
10 examples, but the invention is not limited thereto.

Example 1 Materials and Methods

1. Materials

Test materials comprises a series of full cervical lesion specimens,
15 including: squamous cell carcinoma (SCC, n = 20), adenocarcinoma (AC, n=20), and normal cervical specimen (n=10). All of these cervical specimen, ovarian specimen, and colon cancer specimen were obtained from Tri-service General Hospital, Taipei, ROC. Each specimen was subjected to genomic DNA extraction by means of
20 QIAamp DNA Kit (QIAGEN), and was used in the comparison and analysis of DNA methylation condition within genome-wide DNA methylation. Prior to the analysis, the quality of genomic DNA was checked by Bioanalyzer (Agilent). In this example, 10μg of fragmented DNA was subjected to MeDIP (Methyl DNA IP) assay.

25

2. DNA methylation analysis by MeDIP and CpG island-Plus-Promoter arrays

Genomic DNA was fragmented to the size ranging from 300 to 1,000 bp by BioruptorTM UCS-200 (Diagenode). We immunoprecipitated it for overnight at 4 °C with 30 µl of polyclonal Anti-5'-methyl cytosine antibody (Abcam) in a final volume of 100 µl IP buffer (0.15% SDS, 1% Triton X-100, 150mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM Tris and 0.1% BSA). We incubated the mixture with 120 µl of Protein G Sepharose (Amersham) for 2 h at 4°C and washed it twice with 1 ml low salt, high salt buffer, lithium chloride and TE buffer. We then treated twice the protein G with elution buffer (1% SDS, 0.1M NaHCO₃) for 15 min at room temperature and recovered the Methylated DNA by phenol-chloroform extraction followed by ethanol precipitation. The enriched methylated DNA and input DNA were amplified by Whole Genome Amplification Kit (Sigma). Enriched and total DNA was end-labeled with Cy5 and Cy3, respectively, and co-hybridized to the CpG Island-Plus-Promoter Arrays designed and synthesized by NimbleGen Systems, Inc. This array contained 385,000 50-75 bp oligonucleotides tiled every 100 bp across the 24,659 HG18 RefSeq promoters (800 bp upstream to 200 bp down stream) and 28,226 CpG islands, present in duplicate.

Each feature on the array has a corresponding scaled log₂-ratio. The log₂-ratio is normalization to center the ratio data around zero. From the scaled log₂-ratio data, a fixed-length window (500 bp) is placed around each consecutive probe and the one-sided

Kolmogorov-Smirnov (KS) test is applied to determine whether the probes are drawn from a significantly more positive distribution than those in the rest of the array. The resulting score for each probe is the -log₁₀ p-value from the windowed KS test around that probe
5 (Scacheri et al, 2006). We detected enriched peaks by searching for at least 2 probes above a p-value minimum cutoff (-log₁₀) of 2. Peaks within 300 bp of each other are merged. Differential methylation regions between SCC/AC and normal cervix within 2500 bp upstream of transcription start sites were selected for future
10 validation. Finally, p-value data was viewed using SignalMap (NimbleGen).

3. Bisulfite modification, methylation-specific polymerase chain reaction (MSP) and bisulfite sequencing (BS)

15 A DNA modification kit (Chemicon, Temecula, CA) was used according to the manufacturer's recommendations to convert 1 µg aliquots of genomic DNA with sodium bisulfite to preserve the methylated cytosines. The final precipitate was eluted with 70 µl of pre-warmed (55°C) TE buffer for MSP.

20 Normal DNA of human peripheral blood was taken and subjected to bisulfite modification, which was used as the control group having un-methylation promoter sequence.

MSP was performed according to prior art. In short, 1 µl of modified DNA was amplified using MSP primers (table 1) that
25 specifically recognized the methylated gene sequences present in the bisulfite-converted DNA. Methylation-specific PCR was done in a

total volume of 25 µl containing 1 µl of modified template DNA, 1.5 pmol of each primer, 0.2 mmol/L deoxynucleotide triphosphates, and 1 unit of Gold *Taq* DNA polymerase (Applied Biosystems, Foster City, CA). MSP reactions were subjected to an initial incubation at 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, and annealing at the appropriate temperature for 30 s and at 72°C for 30 s. The final extension was done at 72°C for 5 min. Amplification products were visualized on 2.5% agarose gel containing ethidium bromide and illuminated under UV light.

10 Table 1. The sequences of MSP primers

Gene	Primer	Sequence	
DBC1	Forward (F')	5' gtttcgctcgttttcgttcggagatc 3'	(SEQ ID No: 5)
	Reverse (R')	5' gctctcgctctcgctattactcgct 3'	(SEQ ID No: 6)
PDE8B	Forward (F')	5' tgtgtatgcgcggtttttcggtc 3'	(SEQ ID No: 7)
	Reverse (R')	5' acctatatatccgccgctccgctc 3'	(SEQ ID No: 8)
PTPRR	Forward (F')	5' cggcgttggtatgttttagtagtc 3'	(SEQ ID No: 9)
	Reverse (R')	5' aattacgaataaaaaaacaaaaacgctc 3'	(SEQ ID No: 10)
ZNF582	Forward (F')	5' tgacgggtttttgtttatcggttattc 3'	(SEQ ID No: 11)
	Reverse (R')	5' cgaacgcaaacgtacctacgc 3'	(SEQ ID No: 12)

M: The primers can specifically recognize the methylated gene sequences present in the bisulfite-converted DNA.

All MSP data were derived from at least two independent modifications of DNA. The absence of signal in duplicate experiments was scored as negative methylation. PCR product obtained by using
 15 MSP primer (M) that can recognize specifically methylation gene sequence was constructed into a pCR4-TOPO vector (Invitrogen, Carlsbad, CA). 5 independent clones were selected and were subjected

to bisulfite sequencing (BS). Primers used in bisulfite sequencing (BS) were listed in Table 2. Bisulfite sequencing was carried out using 377 Auto-sequencer (Applied Biosystems, Foster City, CA). Sequenced results were shown in Sequence List. Sequence numbers in bisulfite sequencing were: DBC1_BS (SEQ ID No: 21), PDE8B_BS (SEQ ID No: 22), PTPRR_BS (SEQ ID No: 23) and ZNF582_BS (SEQ ID No: 24), respectively.

Table 2. The sequences of bisulfite sequencing primers

Gene	Primer	Sequence	
DBC1	Forward (F')	5'ggttaagtttttttyggygtagtt 3'	(SEQ ID No: 13)
	Reverse (R')	5'tactccctctacccractctctc 3'	(SEQ ID No: 14)
PDE8B	Forward (F')	5'tgtggygtagaggattattagtttgt 3'	(SEQ ID No: 15)
	Reverse (R')	5'ctaaaaacraaccatccctc 3'	(SEQ ID No: 16)
PTPRR	Forward (F')	5'ggaattttatttgaaatttttgt 3'	(SEQ ID No: 17)
	Reverse (R')	5'cccactcaaataaaatactattaaaaaac 3'	(SEQ ID No: 18)
ZNF582	Forward (F')	5'tagtgayggtttttgttattyggtatt 3'	(SEQ ID No: 19)
	Reverse (R')	5'taaacrtaaaacaacccracct 3'	(SEQ ID No: 20)

10 Example 2 Screening of methylated target gene in cervical cancer

After screened by CpG island-Plus-Promoter arrays, four target genes that might have been highly methylated in the cervical cancer cell were screened, namely, DBC1 (SEQ ID No: 1), PDE8B (SEQ ID No: 2), PTPRR (SEQ ID No: 3) and ZNF582 (SEQ ID No: 4), respectively. Their detailed information was shown in Table 3. It could be seen from Table 3 that, among these four genes, except DBC1 that

was known to be associated with bladder cancer, little study up to date had revealed the relation of those genes to cervical cancer.

Table 3. Characteristics of methylated genes in cervical cancer that were identified using a CpG island-Plus-Promoter microarray.

Gene	UniGene	Chromosomal location	Full name	SEQ ID No
DBC1	NM_014618	9q32-q33	deleted in bladder cancer 1	SEQ ID No: 1
PDE8B	NM_003719	5q14.1	phosphodiesterase 8B	SEQ ID No: 2
PTPRR	NM_002849	12q15	protein tyrosine phosphatase, receptor type, R	SEQ ID No: 3
ZNF582	NM_144690	19q13.43	zinc finger protein 582	SEQ ID No: 4

5

Example 3 The analysis of methylation state of target gene in cervical lesion specimen by bisulfite sequencing (BS)

The target gene : PTPRR

Test specimen groups:

- 10 1. HeLa_0: HeLa cervical cancer cell line;
2. HeLa_10D: HeLa cervical cancer cell line (HeLa_0) treated with 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC);
3. HeLa_DT: HeLa cervical cancer cell line (HeLa_0) treated with both of 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC) and 0.33 μ M TSA (Sigma Chemical Co., St. Louis, MO);
- 15 4. AC: Cervical adenocarcinoma specimen;
5. SCC: Cervical squamous cell carcinoma specimen;

6. Control group (normal): normal cervical blood DNA as the control group without methylation.

Each of those test specimens described above was subjected to bisulfite modification, and then bisulfite sequencing (BS) to analyze whether the target gene (PTPRR) in each test specimen has been hypermethylated or not. The result was shown in Fig. 1, where black indicated methylation region, and white indicated un-methylation region. The target gene PTPRR had not been methylated in the control group and the adenocarcinoma, while the target gene PTPRR had been hypermethylated in HeLa cervical cancer cell line (HeLa_0) and cervical squamous cell carcinoma specimen (SCC). Consequently, the methylation rate of PTPRR could be used as biomarker to screen whether there was cervical cancer or not.

In addition, in order to ascertain whether methylation rate of the target gene in cervical cancer specimen could be regulated through DNA methylation, HeLa cervical cancer cell line was treated with 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC) (Sigma Chemical Co.). The DNA specimen extracted from said cell was subjected to bisulfite modification and then bisulfite sequencing (BS). Result shown in Fig. 1A indicated that, compared with the cervical squamous cell carcinoma specimen (SCC) and HeLa cervical cancer cell line (HeLa_0), the target gene PTPRR in the AZC-treated HeLa cervical cancer cell line (HeLa_10D) had part of region been de-methylated.

Trichostatin A (TSA) is histone deacetylase (HDAC) inhibitors, and can be used to lower or degrade methylation rate. HeLa cervical cancer cell line (HeLa_DT) has been treated with both AZC and TSA.

The result shown in Fig. 1 indicated that, compared with cervical squamous cell carcinoma specimen (SCC) and HeLa cervical cancer cell line (HeLa_0), the target gene PTPRR in the AZC- and TSA-treated HeLa cervical cancer cell line (HeLa_DT) had been highly de-methylated.

In summary, the above-described results had confirmed that the target gene PTPRR in cervical cancer specimen had been methylated through DNA methylation.

The target gene : ZNF582

Test specimen groups:

1. HeLa_0: HeLa cervical cancer cell line;
2. HeLa_10D: the HeLa cervical cancer cell line (HeLa_0) treated with 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC);
3. HeLa_DT: the HeLa cervical cancer cell line (HeLa_0) treated with both of 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC) and 0.33 μ M TSA;
4. SCC 1: Cervical squamous cell carcinoma specimen 1;
5. SCC 2: Cervical squamous cell carcinoma specimen 2;
6. The control group (normal): normal cervical blood DNA as the un-methylation control group;

Wherein cervical squamous cell carcinoma specimen 1 and specimen 2 were specimens obtained from different patients.

Those test specimens mentioned above were subjected to bisulfite sequencing (BS) to analyze whether the target gene (ZNF582) in each test specimen had been hypermethylated or not. The result shown in

Fig. 1B indicated that, compared with the control group, the target gene ZNF582 in cervical squamous cell carcinoma specimen 1 (SCC), cervical squamous cell carcinoma specimen 2 (SCC) and HeLa cervical cancer cell line (HeLa_0) had been hypermethylated. Consequently, the target gene ZNF582 in cervical cancer specimens would be highly methylated.

The target gene : PDE8B

Test specimen groups:

1. SiHa_0: SiHa cervical cancer cell line;
2. SiHa_10D: SiHa cervical cancer cell line (SiHa_0) treated with 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine (AZC);
3. SiHa_DT: SiHa cervical cancer cell line (SiHa_0) treated with both of 10 μ M DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine(AZC) and 0.33 μ M TSA;
4. SCC 1: Cervical squamous cell carcinoma specimen 1;
5. SCC 2: Cervical squamous cell carcinoma specimen 2;
6. The control group (normal): normal cervical blood DNA used as un-methylation control group;

wherein cervical squamous cell carcinoma specimen 1 and specimen 2 were specimens obtained from different patients.

Those test specimens described above were subjected to bisulfite sequencing (BS) to analyze whether the target gene (PDE8B) in each test specimen had been hypermethylated or not. The result shown in Fig. 1C indicated that, compared with the control group, the target gene PDE8B in cervical squamous cell carcinoma specimen 1 (SCC 1),

cervical squamous cell carcinoma specimen 2 (SCC 2) and SiHa cervical cancer cell line (SiHa_0) had been hypermethylated. Consequently, the target gene PDE8B in cervical cancer specimens would be highly methylated.

5

The target gene : DBC1

Test specimen groups:

1. SiHa_0: SiHa cervical cancer cell line;
2. SiHa_10D: SiHa cervical cancer cell line (SiHa_0) treated
10 with 10 μ M DNA methyltransferase inhibitor
5'-aza-2'-deoxycytidine (AZC);
3. SiHa_DT: SiHa cervical cancer cell line (SiHa_0) treated with
both of 10 μ M DNA methyltransferase inhibitor
5'-aza-2'-deoxycytidine (AZC) and 0.33 μ M TSA;
- 15 4. SCC 1: Cervical squamous cell carcinoma specimen 1;
5. SCC 2: Cervical squamous cell carcinoma specimen 2;
6. The control group (normal): normal cervical blood DNA as
the un-methylation control group;

wherein cervical squamous cell carcinoma specimen 1 及
20 specimen 2 were specimens obtained from different patients.

Those test specimens described above were subjected to bisulfite sequencing (BS) to analyze whether the target gene (DBC1) in each test specimen had been hypermethylated. The result shown in Fig. 1D indicated that, compared with the control group, the target gene DBC1
25 in cervical squamous cell carcinoma specimen 1 (SCC 1), cervical squamous cell carcinoma specimen 2 (SCC 2) and SiHa cervical cancer cell line (SiHa_0) had been hypermethylated. Consequently,

the target gene DBC1 in cervical cancer specimens would be highly methylated.

Example 4 Methylation analysis of the target gene in cervical cancer specimens

Methylation-specific PCR (MSP) was used to analyze the methylation state of said four target genes in cervical squamous cell carcinoma (SCC) specimens. The methylation state analysis result shown in Table 4 indicated that, in normal cervical specimen, methylation frequency of DBC1, PDE8B, PTPRR and ZNF582 was 11%, 0%, 9% and 6%, respectively; in cervical squamous cell carcinoma specimen, the methylation frequency of DBC1, PDE8B, PTPRR and ZNF582 was 100%, 47%, 100% and 97%, respectively. It could be known from these results that, in cervical squamous cell carcinoma specimens, said four genes were highly methylated. Consequently, methylation rate of DBC1, PDE8B, PTPRR and ZNF582 could be used indeed as the screening index in screening cervical cancer.

Table 4 Methylation state analysis of the target gene in cervical squamous cell carcinoma specimens

	Target Genes CGI methylation rate (%)	
	Normal (n=54)	SCC tissue (n=30)
DBC1	11%	100%
PDE8B	0%	47%
PTPRR	9%	100%

Example 5 Methylation analysis of the target gene in ovarian tumor specimen

Methylation-specific PCR (MSP) was used to analyze the methylation state of the target gene in ovarian tumor specimens. Methylation state analysis results in Table 5 reported the analysis of methylation states of three genes DBC1, PTPRR and ZNF582 in ovarian malignant tumor specimen and ovarian benign tumor specimen. The results indicated that, the methylation frequency of DBC1, PTPRR and ZNF582 in ovarian malignant tumor specimen was 50.3%, 50.0% and 56.3%, respectively; the methylation frequency of DBC1, PTPRR and ZNF582 in ovarian benign tumor specimen was 2.5%, 0.0% and 12.5%, respectively. The differential methylation level was 53.8%, 50.0% and 43.8%, respectively. Consequently, compared with ovarian benign tumor specimen, methylation levels of said three genes in ovarian malignant tumor specimen were remarkably higher. Therefore, methylation rate of DBC1, PTPRR and ZNF582 could be used indeed as the screening index in screening ovarian cancer.

Table 5 Methylation state analysis of the target gene in ovarian tumor

specimens

	Malignance_Ov (n=28)	Benign_Ov (n=28)	Differential Methylation_level
DBC1	56.3%	2.5%	53.8%
PTPRR	50.0%	0.0%	50.0%
ZNF582	56.3%	12.5%	43.8%

Example 6 Methylation analysis of the target gene in colon cancer specimen

5 Methylation-specific PCR (MSP) was used to analyze the methylation state of the target gene in colon cancer specimen. The methylation state analysis result in Table 6 reported the methylation state of four genes, DBC1, PDE8B, PTPRR and ZNF582, in colon cancer specimen. The result indicated that, methylation frequencies of

10 DBC1, PDE8B, PTPRR and ZNF582 in colon cancer specimen was 100.0%, 100.0, 100.0% and 100.0%, respectively; while methylation frequencies of DBC1, PDE8B, PTPRR and ZNF582 in normal colon tissue specimen were 25.0%, 25.0%, 25.0% and 25.0%, respectively. Consequently, compared with normal colon tissue specimen,

15 methylation levels of said four genes in colon cancer specimen were remarkably higher. Therefore, methylation rates of DBC1, PDE8B, PTPRR and ZNF582 could be used indeed as the screening index in

screening colon cancer.

Table 6 Methylation state analysis of the target gene in colon cancer specimen

	Target Genes CGI methylation rate (%)	
	Normal colon tissue	Colon cancer specimen
	specimen (n=24)	(n=20)
DBC1	25%	100%
PDE8B	25%	100%
PTPRR	25%	100%
ZNF582	25%	100%

5 The cancer screening method provided by the invention has following advantages over the above-described conventional techniques:

1. The cancer screening method, biomarker and use thereof, provided by the invention uses the methylation rate of a particular
10 gene in a isolated specimen as the biomarker to determine the risk of having cancer, and as compared with conventional methods such as cervical scraping and human papilloma virus testing (HPV testing), both of sensitivity and specificity of the inventive cancer screening method are higher than those of the two above-described methods.

15 2. The cancer screening method, biomarker and use thereof, provided by the invention can be used not only as the first line cervical cancer screening, but also in combination with or assisting human papilloma virus testing (HPV testing) as the second line

cervical cancer screening, so as to achieve more accurate cervical cancer screening effect.

3. The cancer screening method, biomarker and use thereof, provided by the invention can be applied on not only the screening of
5 cervical cancer, but also on the screening of other cancer (for example: ovarian cancer, colon cancer and the like) to assist the diagnosis of abnormal specimen.

Many changes and modifications in the above described embodiment of the invention can, of course, be carried out without
10 departing from the scope thereof. Accordingly, to promote the progress in science and the useful arts, the invention is disclosed and is intended to be limited only by the scope of the appended claims.

What is claimed is:

1. A cancer screening method, based on detecting the methylation rate of target gene in test specimen, and using the methylation rate as the screening index to determine the risk of having cancer, the method comprising following steps:
 - step 1: providing a test specimen;
 - step 2: detecting the methylation rate of CpG sequence in at least one target gene of said test specimen, wherein the target gene comprising, PDE8B, PTPRR and ZNF582; and
 - step 3: determining whether there is cancer or pre-cancerous pathological change or not in the specimen based on the methylation rate in the target gene, or using the methylation rate of target gene as prognosis marker.
2. A cancer screening method as recited in claim 1, wherein the test specimen is an isolated specimen selected from the group consisting of cervical smear, ascites, blood, urine, feces, sputum, oral mucous membrane cell, gastric juices, bile, cervical epithelial cell, and post-surgery cancer tissue.
3. A cancer screening method as recited in claim 1, wherein the testing method for the methylation state of CpG sequence of the target gene comprising methylation-specific polymerase chain

reaction (MSP), quantitative methylation-specific polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.

- 5 4. A cancer screening method as recited in claim 1, wherein
the target gene PDE8B has nucleotide sequence as depicted in
SEQ ID No: 2, the target gene PTPRR has nucleotide sequence as
depicted in SEQ ID No: 3, and the target gene ZNF582 has
10 nucleotide sequence as depicted in SEQ ID No: 4.
5. A cervical cancer screening method, based on detecting the
methylation rate of target gene in test specimen, and using the
methylation rate as the screening index to determine the risk of
having cervical cancer, the method comprising following steps:
- 15 step 1: providing a test specimen;
- step 2: detecting the methylation rate of CpG sequence in at least
one target gene of the test specimen, wherein the target
gene comprising DBC1, PDE8B, PTPRR and ZNF582;
and
- 20 step 3: determining whether there is cervical cancer or cancerous
pathological change or not in the specimen based on the
methylation rate in the target gene, or using the

methylation rate of target gene as prognosis marker.

6. A cervical cancer screening method as recited in claim 5, wherein the test specimen is an isolated specimen selected from the group consisting of cervical smear, blood, urine, cervical epithelial cell, and post-surgery cancer tissue.
7. A cervical cancer screening method as recited in claim 5, wherein the test specimen is the abnormal cervical smear.
8. A cervical cancer screening method as recited in claim 5, wherein the test specimen is the HPV(human papilloma virus)-positive cervical cell specimen.
9. A cervical cancer screening method as recited in claim 5, wherein the testing method for methylation state of CpG sequence of the target gene comprising methylation-specific polymerase chain reaction (MSP), quantitative methylation-specific polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.
10. A cervical cancer screening method as recited in claim 5, wherein the target gene DBC1 has nucleotide sequence as depicted in SEQ ID No: 1, the target gene PDE8B has nucleotide sequence as depicted in SEQ ID No: 2, the target gene PTPRR has nucleotide sequence as depicted in SEQ ID No: 3, and the target gene

ZNF582 has nucleotide sequence as depicted in SEQ ID No: 4.

11. An ovarian cancer screening method, based on detecting the methylation rate of target gene of test specimen, and using the methylation rate as the screening index to determine the risk of having ovarian cancer, the method comprising following steps:
- 5 step 1: providing a test specimen;
- step 2: detecting the methylation rate of CpG sequence in at least one target gene of the test specimen, wherein the target gene comprising DBC1, PTPRR and ZNF582; and
- 10 step 3: determining whether there is ovarian cancer or cancerous pathological change or not in the specimen based on the methylation rate in the target gene, or using the methylation rate of target gene as prognosis marker.
12. An ovarian cancer screening method as recited in claim 11,
- 15 wherein the test specimen is an isolated specimen selected from the group consisting of ovarian cancer tissue, ascites, blood, urine, and post-surgery cancer tissue.
13. An ovarian cancer screening method as recited in claim 11,
- wherein the testing method for the methylation state of CpG sequence of said target gene comprising methylation-specific polymerase chain reaction (MSP), quantitative methylation-specific polymerase chain reaction (QMSP), bisulfite
- 20

sequencing (BS), microarrays, mass spectrometry, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.

14. An ovarian cancer screening method as recited in claim 11,
5 wherein the target gene DBC1 has nucleotide sequence as depicted in SEQ ID No: 1, the target gene PTPRR has nucleotide sequence as depicted in SEQ ID No: 3, and the target gene ZNF582 has nucleotide sequence as depicted in SEQ ID No: 4.

15. A colon cancer screening method, based on detecting the
10 methylation rate of target gene of test specimen, and using the methylation rate as the screening index to determine the risk of having colon cancer, said method comprising following steps:

step 1: providing a test specimen;

step 2: detecting the methylation rate of CpG sequence in at least
15 one target gene of the test specimen, wherein the target gene comprising DBC1, PDE8B, PTPRR and ZNF582;
and

step 3: determining whether there is colon cancer or cancerous
pathological change or not in the specimen based on the
20 methylation rate in the target gene, or using the methylation rate of target gene as prognosis marker.

16. A colon cancer screening method as recited in claim 13, wherein

the test specimen is an isolated specimen selected from the group consisting of ascites, feces, blood, urine, and post-surgery cancer tissue.

17. A colon cancer screening method as recited in claim 13, wherein
5 the testing method for the methylation state of CpG sequence of the the target gene comprising methylation-specific polymerase chain reaction (MSP), quantitative methylation-specific polymerase chain reaction (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometry, denaturing high-performance
10 liquid chromatography (DHPLC), and pyrosequencing.
18. A colon cancer screening method as recited in claim 13, wherein the target gene DBC1 has nucleotide sequence as depicted in SEQ ID No: 1, the target gene PDE8B has nucleotide sequence as depicted in SEQ ID No: 2, the target gene PTPRR has nucleotide
15 sequence as depicted in SEQ ID No: 3, and the target gene ZNF582 has nucleotide sequence as depicted in SEQ ID No: 4.

ABSTRACT OF THE DISCLOSURE

A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation rate of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes are consisted of PTPRR, ZNF582, PDE8B and DBC1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in at least one target gene; wherein the method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and the like.

15

SEQUENCE LISTING

<110> Hung-Cheng Lai

<120> Cancer Screening Method

<130>

<140>

<141>

<160> 24

<210> 1

<211> 5000

<212> DNA

<213> Homo sapiens

<400> 1

ggtcttcacc tgaagttgcc tgactacgtt gtctcagatt gatttcagaa ctgcattatc	60
agcagggcag ctgttgcccta ctaacagtca tggaagtaga tctcagctgg gggatgatgg	120
ggaaacaaag agaaagatag ggacgaataa aggaaggaat ggggcacaga cagaaagaga	180
gagagagaaa agaaagaaag gaggagaggc aagagatagt gacctgggggt ttcataccgc	240
ggtgggtggg agaaggagtg tgtgtgggtgg gcgtatttct tctgtgtcag aatcaaagtc	300
agaactgacc tggggaacct gtgttcaaga cctgaacctg gaccagaagc caagggaag	360
agaaagttgc ccaagaaaaa agggagaaat ttccaccagg cgaaaataga aatcgctgac	420
tgggtttgtg gctggagagc tgtccgtggt gctgactcct cctcattggg attccagtga	480
aggctgagaa gctctgcact ggctgctcct cctctccctt tctctcccc tcagtctga	540
ccttctgaga cccaggatca ttctggctag ctcgatgtct tctcctctct ttctcccttt	600
ctctttgtcg attaaataat ttttcccgag ttcccagttc atcaactcaa catttctctt	660
ccattttgtt tcaagactcc tcttctcca attagttcac tggtctctag attgttctag	720
gcctccctgg tggtcacatc tctctcttat catcctttga attaaaaaac aaacaaaaaa	780
catacaatgg caatcataaa agcagacaac atgcaactgag cactcactag gtgtcaggga	840
gcagtctaag tgcctttgca tacattaact catgagcagt ctaagtgcct ttgcatatat	900
taactcatta caattccaca tcaaccctat tagatgggta gatataattat tattctatta	960
aacagacaag gaattgaggc ttaaggggta agtgatttca ccaagaccag acagctacag	1020
gactccaacc tctctggagc ctgcacttct actgaatctg gctcttttac atattccaac	1080
accttttct atgacttctt gcccctccat ctggtagcct taatgctttc tattcttgcc	1140
taatcttcag gggactaggg atctgcattg ctgatttggt ttaaatacaga agggaagcaa	1200
agtaaacaaa cataccaaat gtgcgctgtg tgggaattat catacgaggg ctttattttc	1260
tgcttcagga agaggcccta tgttagcagc cccagcctgc attcaggctg attgcagagt	1320
atttttgctt ttattttcat gtcttagtcc ctgtaccctc gccccctccc cgcctctggt	1380
ggtctccaga gaacttcgtg tcccctcagc ttctccctcc tacatctgc ctacgtagag	1440
aagctcttgc ttcatcttg gaggttacgt gggctctcgc ctacacaccg agagaaacaa	1500
acagtgtcaa acactcacag agagacgcgc agacacaaac ggaccacac gggcaactcc	1560

cgagacaaaa	cccacactcg	atggatccac	gcggccgtgg	aaacacctgc	cgccccagaa	1620
acactcaggt	actcgcgaca	cacacagtac	agtcacgctt	aagggcacca	ggattccggg	1680
tttgcgcgta	tgcgcggtec	ctttggatgc	tcgtgcgcac	agacacaaca	ccctacacgc	1740
cccagaccca	cgaaactccc	tacggctcag	ccccagccca	cccgggcccgc	ccttccctcg	1800
aggcgccctc	ccgtctctcc	tcctctcgct	tcctctcctc	ctccgcctaa	agatgtacaa	1860
aacactcctc	ggaagcaacc	ccggcggttc	gtctctccct	ccccgcccc	cggcgcgcgc	1920
teccccattc	attttcggcc	gtcgccggct	aagtcctctc	cccggcgtag	cccggcctcc	1980
gccgctcccc	gcccggagac	cgcggcgcac	ttggacttcc	ctctccattc	gccagccgcc	2040
tcgtccccgg	accccacggc	tgcaaaactga	tcctggcgcgc	ggggaggagg	agagcgcagg	2100
cgagcgaacc	cgcgagagag	ggagagagcg	agcgagcaac	agcgagagcg	agagcgagag	2160
agccgggagg	cagagggagt	agtgaccgcc	ttccggagcc	gggattcatg	cctgtcctcg	2220
ggaccagcga	aggggacttt	acggctgagt	atgagccagg	ctgctaggag	ccaggtaccc	2280
ccacgcctgc	agtcctccgc	ccgtgcccg	aatgcgagct	gcacgcaggg	ctctcccaag	2340
ttccaccga	gccgaataaa	aagcgctctc	ccgcagctct	ccgccaaga	cggacattga	2400
ctccaggtaa	ggcggcgcgc	ggtgcagcgc	cccgcagccc	cgtgcctt	ggaccgcgcc	2460
ccgggcccga	ttcggggcgt	ccccgcctc	ctctgccctt	ccccctaccg	gcaccttgt	2520
ccgtcttca	cctggccgcc	ccgccgcctc	caagtcttct	ccagttctag	ggaggggggt	2580
cctgtgcctg	gggtctaaag	ggctaattgc	gggtttgagt	gagtggcgtg	tgtgtccccg	2640
cgcgtcccg	acgtgtgcac	catggtggga	acttgatgtg	gtgctagtgt	gtttgcgtgt	2700
gcggcgtcgt	ttgcgtttga	tgctgtgttt	cgtggtgtgt	gtgtgtgtcc	gtgtgtgtaa	2760
gggaggggtg	aagagagaga	ggtcctataa	cctacttacg	gcgcgatgtg	tgtgtgcatg	2820
tttgtacgta	tgtgtttgta	tgtgtgccct	cgtgtgtctt	tttaattagg	tctctccagc	2880
ttacacggaa	tgggaccttt	actataggat	cacgtagtca	ccgggaaacc	cgtgtggac	2940
ttctcttgg	ggctctgggc	ttggggtttg	gggaggatta	tggggctgta	gatggcacct	3000
tatttagccc	aatgtttgta	cgtttgaagg	aaaattcctc	caaacgggtg	aatcctgcta	3060
cactgggacc	cacagcttaa	tatgaaagag	acatggccaa	cccccgaggc	aaatgagacg	3120
ctgtcacttt	aaattctaca	ctgggcagac	tccaagattc	tgatgggaat	ttggagacac	3180
tggatagtgg	gtgacagaga	aagggggaag	tcagcgggtg	gctccttata	tggggccttg	3240
aaagtctggg	atagggattt	accctgcate	ccgtttgca	atcaacagag	cccctccggc	3300
ttctgttgg	tttggggagg	atctggcaag	tttgcattga	ttccccctag	gggaaaggag	3360
aaagcgtcct	cggggacttg	ctcatccatc	acagttgcaa	agggctctcag	aggaaatttc	3420
atctggggcg	gctgtggatg	atatggaagg	agatggatgg	ggcactttcc	taagacagat	3480
tcgtctttct	ttccccattt	caggcgggga	agcccccaga	gagtctctcc	ctaaatatgc	3540
ctctccatgg	ctccccctga	gtagggggga	tattgagaga	aggcagagag	gtggagaggg	3600
agagagagag	agcaagagcg	agagagaggg	agacagagag	agagagtgtt	tcagtactga	3660
gggagatcta	caatttgaaa	aggggctgtg	agtgtggaac	ccatgacaga	atgtggcagt	3720
aattgactta	aactgctgtc	ggtttgccac	tcgcgtctct	cacttggtct	caaaatactg	3780
ccaagggcag	gggggcgggtg	gaggaatctc	agccaggaag	gtagtttggg	tcaagccct	3840
ctttcttctt	tcctccatct	cctgggaggc	tccttaggta	ggtccttgg	ccacctggc	3900
ttgtactgt	tgggcttggg	ctctggggcc	agccattgat	ttgattccca	gctgcctctt	3960
aaaggccttg	cctactcagc	aaaaatgctg	agttttactg	ctgttagcat	ggcttccaga	4020
ctcggcagct	gttactttct	caaggtaagc	ggcagccgtt	ctgtctctcag	gcagggaggc	4080
taggagaaga	caagggtgtg	gacgtggga	cacagcctct	tgtctagctc	agcacggagg	4140
ggccgctgaa	aagccctctt	aggggaaaaa	agtagaaata	tatttggcct	aaaaaatgta	4200

cacatatatt	ctaggaagat	atatatatat	atatatatat	caatcacaca	cacacacaca	4260
cacacacatg	tgttcatatt	ctggggagag	ataaaagcaa	acatgtat	gtaggaacct	4320
gccctagtgg	gtgggttcta	cctgcaggca	cttgcagaca	taccattctc	tgtccagagg	4380
ctgatacctc	aggctgaagc	cttcacatag	ccacagagaa	tctccttcag	gaaactcatg	4440
tcagggcaga	gctccctgga	ttatcttggg	taggggggtac	tagggccaag	gaggagaccc	4500
atTTTTgga	actgcctcat	tttctctctt	tctaattca	cagacgatcg	aaactggaag	4560
gaatattaaa	gagcagaaag	gcaggactct	gtggcctaaa	gagggaatga	gaattcccca	4620
acattcagta	gtgggttagt	ggcatgccca	ggactagaat	ctaggcttat	caatcagcta	4680
gatcaatacc	ctttccactc	ctcccagcaa	tatacactct	aggactgtat	attgctccca	4740
cccctatctt	gccaacctgc	caccatgacc	cctaccaaga	caatcgcttg	tcttccctca	4800
tcaaacttca	cattttcaga	gatgcatttc	agggttttct	tatctggaaa	catggccctg	4860
aagagaaaag	atccaatgcc	tcaatcacta	ttcccgaag	acacacacac	acacacacac	4920
acacacacac	acacacacac	acacacacac	acacacacgg	tgggtgggggg	aggactgaga	4980
gagagacaga	gagagaacat					5000

<210> 2

<211> 5000

<212> DNA

<213> Homo sapiens

<400> 2

agaacaactc	tgaagcatca	tcccaccttc	agaatcctcc	ctgcagggat	gcctgaggct	60
tgggtcaattt	ctccctctgc	tcaagcttgc	ctccctccat	tccctccctt	tatttctctc	120
cacaaatgtt	gactacaaga	gcacttccta	aaaagcctcc	ctctgcctgc	taaacaccat	180
ctcagaatct	gcttctagga	ggacccaacc	tgtgcagaaa	ttttatgagc	aatttgccctg	240
tccattaaaa	aatacagcat	agacttttct	caggtttagct	ggagatggag	tttttttgta	300
tcaaaaaaag	agagctaaac	tgagaagaga	agcaaaggta	gaagaataag	gtagactctt	360
ccctgtataa	ctgaatttgg	gattgggaat	gatatcttgc	ttctctatga	aatttagaaa	420
ctgtcttttg	aagtcttcat	ccagtcacat	ccaagagtgg	tccaggaaga	aaaaggaaaa	480
taagaatgaa	aaaaaaacaa	aaaacaaacc	ttaaaattgg	atacttcttt	gtgccttgca	540
ttaagcctct	atgttactgc	ccttgctccg	ataagcaact	ctagataaaa	tcctttctta	600
gaccatctaa	tttatctccc	cgtgccattg	tgaaaatcgg	gcaggaatta	ctgcgggaac	660
cagtactga	atgggcagtg	gtgtctcgca	gctgtaactc	agagtttaca	agggaaggat	720
gaacagcagc	catccttcta	aaggcattct	tcctctcctc	cagcacagct	cagtctgtgc	780
atgcctcacc	aaggagaatg	agggaaggcc	ttgttgactg	cccagcccag	agtgtgagga	840
acagcagttg	acatgggcgg	ctggacggga	tagaaaccag	catgaacatt	tagtgacacc	900
taaggaagag	gtgaaaatgg	gggagaaagc	caagaaccat	cagacagctt	ctttctgttc	960
ttgccttgga	tcttagggga	acgtatgtgt	tcaagggtgc	cttctctcgc	agggcctccc	1020
atcccttggc	acaaacttcc	aaacgatgag	tagacatgga	atgggcttct	tctgaagact	1080
gggtcaccat	ccaactcagc	cttcggagta	ggcgggtggg	ctgggggaag	aggacggaac	1140
catgaggtct	ctccatcact	tcccgggtgt	gttgagaggc	aagcaaatgc	ggtgggtggg	1200
cctgggctgt	agggcccttg	ccatttcggg	aggggcctcc	tgggtgtttg	ctctgggatg	1260
tgtgaaaatg	tgttggtgaa	aagcgagagg	cttacacagc	ccttcagggg	aagaggggct	1320

ggggcgctgg	gggcggcgctc	gggatgagtg	cagaagagac	gaggcctctg	gacagcggag	1380
gaggagggga	gggcgcccag	gcgcggtgcc	agctgccgcg	cacaggggce	ccgcggcgga	1440
gccgagccgc	gggcacgctc	tgccctgtcg	ggagagctcc	gggagcggcg	ggaggggcgg	1500
aggggcgag	tggggcccgg	gcggctgcgg	ccgcggagcc	ggggcacctg	aggaggaagg	1560
agggtgggag	cgagggaggg	aggggacggg	cgcagaccga	aagtggggaa	agaaggtgca	1620
ggcaggcggg	caggcgggcg	ggcgccctgg	cccagggccg	cgggtgcggg	agcccggcga	1680
ggtcgagctg	ggcggcgggc	ggggccgcgc	cgagggagga	ggggaaggcg	gaggcgcggg	1740
gagcgtgttt	ggggcgccgc	ggcggggagg	gtggcgggcc	ctggtgcgcg	cggggcgctg	1800
tgtatgcgcg	ctccccgct	cggggaggaa	gatggcccaa	aagggaagt	tggggtgacg	1860
cgcgcggtcc	ccggaggctc	ggcggggggc	accgcggcca	gcccgcggga	gcggcggaca	1920
cacaggccgg	ggggcgcgca	gtccgggcgc	cgccgcggcc	gccccctcac	tgcaggtggc	1980
agcgggtgcg	ctgggtcccg	gcggccgcgg	gcgcgggcgg	gcgcgcgggg	gagcccggcc	2040
gagggatggg	ctgcgcccc	agcatccatg	tctgcagag	cggcgtgatc	tactgccggg	2100
actcggaaga	gtccagctcg	ccccgccaga	ccaccagcgt	gtcgcagggc	ccggcggcac	2160
ccctgcccgg	cctcttcgtc	cagaccgacg	ccgccgacgc	catccccccg	agccgcgcgt	2220
cgggaccccc	cagcgtagcc	cgcgtccgca	gggcccgcac	cgagctgggc	agcggtagca	2280
gcgcgggttc	cgcagccccc	gccgcgacca	ccagcagggg	ccggaggcgc	cactgctgca	2340
gcagcgccga	ggccgagact	cagacctgct	acaccagcgt	gaaggtaaag	gccccgcgct	2400
ggcacacgcc	gtggggggccg	tccgccccgt	cggcggggct	cgcacgggta	gggggctccg	2460
gcggagttag	gtgaccgtga	ggcggtttgt	ttggagaggt	tgtactaag	gaggagttaa	2520
cttttcattt	gtggagatga	tgggagccca	ggaaatgttg	tcagaaaaag	gcccctggag	2580
gggtccctga	agcgtcccta	gctgggtcct	ggggactggg	cggggaaggg	agcgcagaag	2640
gaagcaggtg	ggctggcctg	tccctccttg	agggcaggaa	ggctgtggct	tggtttatgc	2700
aggaagaggg	gtggggacca	ttgagagcat	tcgggtggca	gtcctgttga	atgaaatctg	2760
agcactgagc	tggatttgcg	tgccttgtag	gtgactgggt	cagttgcagc	accaggatag	2820
atagtgcgcc	atattccgat	ttttacctgg	gattaccage	caggctggag	tctcagcaca	2880
ggaaccgagc	gtagggattt	gtgaatgaat	gagtgttcgt	gttttaagag	atgtgggaac	2940
ggagcagagt	ggaacctgtt	gtttgtcact	gtaacgtttc	tctgggttgg	ctgcatecta	3000
gacagaattg	agagaaccgg	gccatgagtt	cggagtgtca	gcagagccac	cgtgagggga	3060
cgtggtttcc	agtgcagtac	agctgtctga	ggatgattct	gcacatacaa	ctgatcttcc	3120
cagagagtgg	gattttgagg	aagtggaaaa	aattgttttag	atggttaaag	cagtcgctaa	3180
atattttatt	cttaaagaca	gaagaaaaat	aattatttaa	atagtgtcct	cccgtatgtt	3240
ctcaaagtac	cgttaaatec	aagaggcttt	tcattgtgta	aatctgggca	ctgggtcttt	3300
tttcctttca	gcaaacaaga	taacaatggc	atatectatt	gtacagagag	aaaaaatac	3360
tcctaattgc	agatagaate	acagccttta	cctgggtcaat	aggttaccaa	gaaccattcc	3420
atggattatt	tgtcaaagac	acatttgtat	ttttaatagt	taaaaacttg	gtcttcattg	3480
gatgaaggca	gcccacagtg	gaggagttag	gagaaggata	acatgttttg	gcttcaatct	3540
ggaagtccaa	aagtttttta	atgaacctat	ttttttttta	acagcatctg	attgtttaac	3600
atgaagcttg	actgatgttt	gcttgttggt	gcagtgtttc	tctggcagta	atcataatca	3660
ccattatagt	aaaaacatcg	tttattgagc	acctactatg	tgccaggagt	aagctttctc	3720
tcctaactat	tgaatgttaa	cagtgtgate	ttagcatagc	atgtctgaag	actagagtct	3780
aggatttlat	acagtacaaa	cctaccagtt	gcccattcgt	tacagaggca	tgtgctgaac	3840
gctatacttt	gcttttgtca	agctctctct	ctctccccct	ccctgtttcac	acaaagttag	3900
ctttaggagc	aattttcagg	gatgaaaatg	ttaaatttgg	tgaaaatatt	aagttgggat	3960

attatcagta aagaccatcc ttttgcctga cggttgaaga cctgaagcag tagttcaaaa	4020
ttgtgacagc tcatgaactt tgtgatactt tttttggttg ctccagagaa attgtgaatt	4080
tttgttttct agaatatcta taatctcagt ttagtacttg gcaactctag ctactccatg	4140
tttgttcagt agaagaaaga atactgaatg aaccattctt gtacattttt aatacttccc	4200
tcaagaggct gcttagagac caaatgaagt aaaaactgaa gggacaatga gcccgaatta	4260
ttagcagctt gtataaactt gtattaatct cattgctact tggcttaagt attaaaagge	4320
ttgacctggg taggagttta actcattttg ctttatcaag aagattccca aataagagct	4380
taattcactc taaccatta ctgggaatgt tggaaatgaa acccctgggt cattgactta	4440
acactacttt gcatttgttg gatctcagaa agtatatatt tgaagtgaat tttgagacca	4500
gagttattta tgcaaatctt acagaattat tatcacagaa ctgccctaata atatttaata	4560
gtatcctttt aggctgtga ctcggtgttg tattgtcttt tctcaatcgt aaagttcaca	4620
tgttctgtgc ctttttgttg ctgagataat ttataaaaa ctttacattc atttttttgt	4680
agactaagca ttcttttttt gccgtaagag ttgagatag ttgctaggca cgtggtgggtg	4740
ccccaccct ttccaaagca cacagggtgga aaaataaaat ctttaccatt tggctctgtt	4800
tacagtgggtg gaaggttgta atagtttcca cccctcccc ctggccattt tacatcaatt	4860
atgaagtgta tcttcattat ctacttggcc tctggtattc ccagagtgc aaaaatgtgt	4920
gcttgatctc tctctctctc ttttctagca ataattcacc tcattaagct tttagaatga	4980
tgaggcatta tgatgtcaaa	5000

<210> 3

<211> 5000

<212> DNA

<213> Homo sapiens

<400> 3

aagaaaaata gacctattgt aagtgggata caattatttt tccctaacct ccagccctgc	60
agcattttcta gtaacagatg ttagatgaga agagttattc ttctaagctt tacagaatgc	120
taaataaatt atctcaaagg ttgactcagt aagaatttca aagagttaat tgtcagtatt	180
gaactttgtc aactatcatt ttcatattt catttttgag tatctatttt gcatgaggca	240
ttgctctagg gagttgggac atatcaataa agtcatcaaa gttcttcaac attggagctc	300
aaattctgtt ttgcgggggg gagtagggaa atagatacta aacaatagat ttataagta	360
attatttttg tttgttagaa agtgatacgg gaaaagcaaa ctggaggaca gtgaatcagg	420
aataggagaa gaggttcag cttagagtgg ttgggatga aatgatagt ccacagaaat	480
ggagtgtgcc acacgcattg gggagtaggg ggtggagcac gttgctagag aggggctaga	540
catggagata tgtctctatt ttcagcagag aaggcctgtc aagatattaa aagtacatct	600
cattgtcccc ttctccact tgttgagtg cttcctggcc ttgtctctca gagctgaaga	660
tgacataaat cataaaagaa ataaatggta ccgcctgggc tctctgatct tataaggtcc	720
cacctaattt aagctctggt ggatagccta ttcccatia gttgtctcaa ttcacagagg	780
atggagaaag aaagcactga atgagatgtg cagctcaact caatgggcac ttgttagccc	840
caattatttg gctaggacaa ctttattcaa gttaatggaa tacaaaactc agcagttctt	900
atggagactt caatgtgctg tagaacaac cacagataaa tgaactgtct gaaagaataa	960
tatgaggcac ggctaaacaa gtgttggtga agagaaagat cactgtaate tagagttagt	1020
tagagttagg gctttctgga aaagtgagac caacattaca ctttcgaaaa ctagtgtggt	1080

ggtggtgcaa	gtggaggaaa	atgggaaaaga	ggcaacagt	tccataaaga	cacagaggca	1140
gaaagggcag	aggccctggg	atagttaaaa	gagaagtcta	gctgaggggac	ttcttgactt	1200
gactagcagc	aattagccat	gactaataag	gctttccaca	ctccaaagac	ttagatggag	1260
ggataaaaaa	ccatctaata	gcagactgtg	gtagcctccc	tagagacaca	gagctggggc	1320
ggatgagtc	aggcactgac	gtgatccatt	atctttcacc	ttaaagagta	aaagggaaac	1380
taaagttaat	tacctccacg	aaacaaaaaag	gtgccttctt	gtgcttcaat	tacatggata	1440
tattctacta	gtctaaaaag	atctttctcac	ttctttctgt	cactgtgagg	acttgagtca	1500
gaagaaagt	taaatacagt	cattgagctg	gaaagagtgg	aaagagaagc	aaagaggggg	1560
aagctgtagg	aaggacgaag	tcacccccaa	gatacatggt	tactgcttac	accaagcaag	1620
ctgccttggg	aacgcttccc	ccgagcagcc	agaatgctca	gcagtggaa	acacctctat	1680
tctgtaggc	gagtcctggg	aagctgggtca	atctgcaaat	gccaatcccc	agcagtgage	1740
tcggtccacg	tgtaaatcaa	gatttgggga	aagagtaggg	tgggtggcat	ggttgacaat	1800
gtcatcagct	ccctcctctg	actcctgtgg	tcgtgcccc	atctactctc	actcagctac	1860
acccacactt	cggatttgtg	atggacgctg	ggtccttagt	aaccacagca	agtgtctccc	1920
ccgcacttcc	cccttcccc	ccccacccc	cacccccaac	caccacccca	gcgatggagc	1980
ctactctgct	ccaagccgcc	gctaagaccc	ggagaagcgg	aatttcactt	tgaattcccc	2040
ttgcctcgtg	agggccggcg	ctgggcatgc	tcagtagccg	cggcgctgct	gctgggctgc	2100
tgggctggcg	cggagtccac	cctgccgtct	ccgccttggc	ttctgggcgt	ccagaaggcc	2160
aggcatttgc	cgcctctgag	cgttctgttt	ccccctaccc	gcaacctcct	actgctcttc	2220
ctctctccct	ctcttaggga	ggttgaagct	ggtgctggtt	tctgtcggcg	ccacagactg	2280
actgctctgc	aaacccagc	cgaggacctg	aatcccggag	actagaagac	ccttggcggg	2340
ggctctttct	aatagcactt	tacctgaagt	ggggtcgtgg	tggagtcttc	cctccacctc	2400
tcaatgcaaa	cactatgcgg	agagcagtct	gcttcctgc	gctgtgcctg	ctccttaatc	2460
ttcacgctgc	aggttaaggg	ttgccaggct	tagagccgga	gctgtgcatg	agatgggaaa	2520
ctgcacatgc	ttaaggactc	taggaaaagc	ttgccttgcg	aagaaagcct	ttctaaaaag	2580
gtaaaacagg	acagtacctg	acagggaagg	ggtgagggag	tcgtgcacct	ggttgaaaaa	2640
tgaggccgaa	aacttaacct	aaaattagct	cttgattttt	ctttacttta	tacgaaaata	2700
gtgaacattt	tcaatatgaa	tacaggtttg	ctccccctt	cgcctcccct	ccgtctagat	2760
tcctctgctt	tgtttctagg	ctatgcactt	aactgtcaat	ttttcaggag	agggataaga	2820
catcctgcta	gatgtaacct	tttctactgc	agcggctact	acattcataa	ggtctcttgg	2880
tctagcgagc	gctcatagga	aggcattggc	tgtaacctga	tggaccacat	ctccgcccc	2940
aagatcgaaa	tacatgggtc	acattagtga	tgtgcacca	ggctcctttg	gcccctgctc	3000
ttgtcactcg	aattttctaa	gccaataaga	ggaagaaaag	gtttcaaata	gaatcctctt	3060
gtctctttca	gcaccgtggc	tagcgtccgc	tggcatatta	aaaaaaaaaa	aaaaaaaaaa	3120
aaaaaaaaaa	acaattacag	ttccaaagct	gacaaccttg	ggttaggcac	tgtccctcgg	3180
acagatttga	taaggtgtaa	ccaagagtaa	cagtgagact	gtccccaat	ataaatagat	3240
ttgaggcacc	agaatcaata	tcaagtctcg	tgaggaagca	aaccttggga	agtacctgag	3300
agatattata	tgtgggtgtc	ctgctttttg	catacatagc	acctctat	aatgcagaca	3360
gacttgctag	gctgaattcc	ttatcattgt	cacacacaca	tgaacaaaa	taaaatatgg	3420
caggagattt	ttagaaaccc	tactgtgaca	gcagttgtcc	atgcagtagt	cctgtaacaa	3480
ccagagacga	ggcattttcc	ctgagtgtgc	ttctcatcca	atcacacata	tccattcatt	3540
ccttcaagca	acatttgcgt	agtgtatact	atgttctagg	ggtaaatgagt	aaaaataatt	3600
gttctgaaat	tacaatcctt	gcagtatctt	ttttaaaaga	gtgggtgaat	tttattctct	3660
gtgtacaata	gtaggagtga	aatatggtac	tttcttattc	cagctaacgc	tattatttaa	3720

atgtatcatg aatcttttga gcaaataatg cataggatta ttaaagctat tattaaatac	3780
acatgttaat tgttataatt atgatgttat attgtggagt tttcaatagt tctttggcac	3840
attttgagaa gtagaaaata gctatgactt gattattaaa ttatttgcaa acagctgtag	3900
tgaattattht cgttaccaca tacaattctt caatgctgaa atgtgggatg aaaacataca	3960
cattgggttg agttttattht atagtattgc ttaataatag actgacacaa acattcatta	4020
cagaaaaatc tcaattctta ctaaggtagc aatgattht ctggtctgcc aacaatatca	4080
gtgtagtcat tttttcaaaa ctaacatata aaaaagtht aagatcacat ttgatacatc	4140
ttgagtaatt atattcttaa agttataaat aaactgaagc atgtgaaaa catgtcttga	4200
tttactgtag atgaatattht gggatgagaa aaatgaggac ttttgctcat cagatgagaa	4260
acctagaagc ctgtagccct agatthtacc tggagtctg ccaaagggtat tattaccaaa	4320
gccaatccaa tccatctcta ctccaacttht ttaatttgca aaacaaagat aaaaagtaag	4380
attaatcaac caattthtatt ttaataagaa aatgcatttht aggacatttht tatattthcaa	4440
ttgcaagata ctattcattg tattcatatt taatatagta aaatacattg gtgtttttatc	4500
acagcagatt gtaagthttaa tattatagtht ctcttgccaa tttcatttht aatgcatttht	4560
aattthtaaac agcaatttht gggtcacaag ctgtcatcag attaaaatttht atcacagtta	4620
tctaataaca ttgttagggc ttttcatcag aactaaaaca aacacagctc cttggtctaa	4680
gcttctatac atttgagat taagaaaata agtggatggg atgacaaaga tcaagaaatc	4740
aagatatttht tctctacttg ttgaaggtht gagthttht cttttatgga agactthtct	4800
ctcagaacag aggctgactt cataaagaag ggaaatgaat tctatacatt caggcctctt	4860
taactgtaaa gctaattgat ccattthtggg tacgccaggg gtatcagcaa ctgctthtatg	4920
ctggtggaac tgatgacacc ttataatgct ttagagatgg gaggaatgtg ctaacgggat	4980
gtaagtgttc tttttagcta	5000

<210> 4

<211> 5000

<212> DNA

<213> Homo sapiens

<400> 4

gacgacctg aatgatecct gcctectagt acttatactc ttgtgtagec tccacctact	60
tagactcaca gctgatttht tgaccaagag tataatgggtg tatgacttht gaggcttggt	120
tcagagtcag aagtggccat ttcatcatcc tctaaatttht tctttggcag attaatgaat	180
gtgagaaagt aaaaatggta tagaagaaag ttagcctgag agatggctgg ctttgtacct	240
gtttggtctt tttcttctt tttctccata agcaaatact gacgcatgta catatagaca	300
cactcaacac agtgggatgt taaagggaaa ctagagccac tcgccccttc ccaagatcag	360
agaacatagg aaagatgatg actthtthtga tctaccctct cctcttgaac tcgcaacact	420
gtcttgaacc acaataagg tcaagtagga taaatctaca actgtctctt caactgtccg	480
ctcacaagtg tgaaattcaa ccatccttht tgaagthtgc ttttaataatc agtaatcagc	540
aataaccaac ctctgagctt tgcttattat attaaatcat tttattthgac cctcaggaca	600
aagctgcaag cccagcatta cattcttctt tttatggaca aaaaaaaaaa aacaaaacaa	660
aaccgagata ggcacgaaga aactaataaa ttgctgaaat gctattthgaa tccacatctg	720
tctaattcta aaagtgtgct tttccaccaca tcaccgcacc tacaaggaaa atgcagcctc	780
tacctctctc tgaagaatgt gtaaagaggc aatatggtgt gttttggaaa aagcatcttht	840

gcagaaagaa	agcatttagct	tcagtcatat	tagcatcctt	atccagcagc	agtagcatta	900
ttttacatat	cagttactcc	tccccaacaa	ctcaatgaat	tagatgccac	aatcatectc	960
actttcaaat	gtggagaccg	aggcacatct	ctaagactgg	agttcaggca	ttctggtctc	1020
agtcttagag	atggttaagg	gttcacactc	ttaaccattt	attacaccat	agagctcacc	1080
aggtttgagg	gaaacaggat	caaatcaaaa	gagtcactca	ggactccagt	cctcactcaa	1140
ggacaaactg	ttccacctcg	gacagggaga	gtttccgcat	tctgagaccc	agcataacag	1200
gtcctgaccg	gcactctggca	ctcggactcc	caatcatact	ggatcacact	ggctcgggat	1260
gtgtaaagtc	cagggcttct	cacatttgat	gacaccaaag	ccgcctaaaa	acaagagaga	1320
attaacaact	acctacggcg	gtctgatatt	tgcccaagag	atgccgcccc	ataaaaactcc	1380
tttacatctt	tataacgttt	ttattttgcg	ttctccttca	taaccacat	ttaactcacc	1440
atagatgtaa	tgttttaaat	tagttaccag	ataaactctt	acgtttccaa	actttaaggt	1500
tccttcgaaa	ccttctggta	aaactgttgt	tccacggaaa	tgggaacgta	acggatgagg	1560
caatcttcca	cagccgcaca	cagttgtgta	tccaccgcta	aacggtccca	gtcatacatt	1620
caacgaccca	cgcggagtca	gaagctacca	ccacacactg	tcaaaatcac	gcacacacag	1680
tgacggcccc	ttgcccactc	ggtcactcgc	ccacaatctc	tgcctagaga	atcacacgca	1740
gatagcacac	ccagcaccac	agaccccagg	aagcaaccca	gggactcgaa	cacacgaaca	1800
gcactectcc	gcgcactgcg	caggcacgcc	tgcgtccggc	tcaccctgaa	acatcgcgag	1860
atccggcttc	aaggccgggc	tgctgccttt	acgcctaaag	actatgtttc	ccggaagaca	1920
ctgcggcgcc	ggccctatca	tggcgcagca	tcggtgtgct	ttgtgcgtct	gcgccatctt	1980
ccggctgcgc	acggcgaatc	caccggtacc	gtggtggaag	cgcgccttgg	gctgccgggg	2040
gcgcggccgc	ggtggcactt	ggacccgagg	aggcggcagg	tgagaggttc	cggagctttc	2100
caggcgctct	ggggctccagc	aggagctggg	gcccgggcgc	gttgggtctc	aggcctgaga	2160
agaacgcaga	cgtctcgcct	catcgtcgtc	ctgtggcttt	accggcgtga	gactacattt	2220
cccgcgggcc	ctcgcggcgt	gcgctttctg	gcgccccctt	tctgtcttca	gcctcatagc	2280
ccaggtgcat	ggacccctta	ggtgggtgcg	caggggtctc	cgacccccctg	aaattgcgga	2340
tgttttgcat	tcactgttat	gcgtgccttt	tttttttttt	aatctgagag	gaaatcttgt	2400
ttcatgaggt	tctcagagag	ttacaagacc	ccagaagact	tagaaccgct	agtttagaaa	2460
aacttatact	tgggaacatt	ttatatgttc	aaattctatg	tccagcaatg	gggaaacact	2520
tgagtggatc	acaggccatc	ctttgtaaat	aggatatcgt	gcagttaata	caaataatgc	2580
ttataaaagt	ggtcataata	aggaaaagct	gcctattaca	tcatattaag	caacattcat	2640
aattatttca	cttacacgtt	acttagaacc	aaatgtttgt	aatgcagtag	gcaccttata	2700
tactccttta	cagagtactt	cttgtttaac	agttagctca	agaactgggt	aaatgacaac	2760
actgcgaata	cttgggtgtt	ttttcttcca	atttttttgt	tttgttttgt	ttttagcctg	2820
tgtgttagtg	agtttgactt	ctttttgctg	aatgtttctc	aaggattcag	tagttaatat	2880
ctttgcttgt	cagtttttga	tagtcaattt	tgatagtcac	ttggcatecc	attatatggc	2940
tgtgccaaaa	atgattcaac	ctcttggtca	cttgtggact	tgccctactta	cgtactaatt	3000
ttcagttctc	ctattttagca	aatattattg	gacatgcagc	tttgtgcact	gctgtgtctc	3060
tatggaagga	cacatttatg	tgctgataat	ggagcactgg	gcgtgctgtg	tgtaatttgt	3120
ctcttactgt	tccttccaac	tctatcccat	ttgttgatgc	aaggcatgct	ccatgaagtg	3180
gcatgcacaa	agcctcagtt	tgggctgtag	agctttttgt	atattttggcg	gttgggaaaa	3240
gagccaggta	gactttcaaa	ggtgttatat	ttgctgcagg	agagagttaa	atggcctagt	3300
ccttgaaagg	ctttattcta	ggctggggct	atgcaaatga	tgcaggcctt	ctatgctccc	3360
tggcttgagg	gaagccctcc	ttgtccttga	ggtaacatgt	gggtctcagt	cactagaaca	3420
gccctcagca	tcctgtcttt	agacttgcat	ttgcagcaaa	acagaaccac	tggatgttta	3480

ggggaaatgg gagggaaagg accactgggt cccctttgcc ttgcagcagc taaagctggt	3540
tlcctgggggt tgggtgagga tccctttgcc tccccctcct tctcatlttc ttgggtgggca	3600
gagggcaagc aggtggggac ttgtaacttg gcattctagg aactgtgagg caagcctagc	3660
ctctcatgtt tgctctttcc tccccagct ctaccgtcgc aggactctgc ccttcccca	3720
gagaggaacc agaaggagga cctatcagcc cttgaaattc taaaagtcac gtcccttgtg	3780
agttttttaa tcccataaat atttgccttc cttatcttga aactttccac ctgggttcca	3840
tccagaaatt tggttctcag actttcccat tttagggaat aaaaggacca ggcaggagtc	3900
tcctctccca ttgtcctctc ccctctgaca aatgccca gatttattct ctatagcatt	3960
ctgcatctcc tgatggtttt cgtctgctag gaggagaaac tcatttccct gtatgaaatg	4020
agagcatcct ttgtaagaac tgaagtttga agagatggaa tgaatgctta ggagcaatca	4080
catatagaaa agcaggggag gtgggtgttg ttggtttcag tttcagcgca tggtagctg	4140
tcctgctttg ggaatgatta atgattggat atgtaattga ggtttggctg ggaatccatc	4200
aaaaatttga tgccagaatt aaagtctagt ttgacgttgg acagagcatt tgaatctggg	4260
acatcctcca ttagtttctt tagcttaaga ggaagaaaag tacagagctg aggatggtga	4320
gcgatgtagc aagttagatg atcatctagg tgggtgagtg gtcagggtt ggaaaagcct	4380
tagagatctg atccaacctc gggatccaaa ataagaggat gtttgagtca gttgtttcac	4440
ttgatagaaa attgtgcact caataaaagt tatctccatg gtttttcca tgaagaaaa	4500
tgcttgtgtt atgttccaac ataagatga actttcatct ccaagaaatt cttgacttac	4560
atgaaaatcc tgtatctaag atagaaaaca tgtttccata attttaaaaa ataaaatatt	4620
tggggaaaat ccatcagaaa tttttttgt tgttattgtt attccaaaag atagaagtga	4680
taggtctcac cttgagaatt tattgtatgc caagtataga gtgggcagtg tgctttatta	4740
cactgtttct taacaataag gaaaactcca tttagcttga ttttaatttt catcccagac	4800
ctgtacacag agcattgatt tgcagttaaa aggaatgttt gagaacaatt tgatcattct	4860
gttttactca tcccatttc ttctgtcacc ttccacattc agtcccaccc ttcttgttca	4920
acaaaacaac cccccctccc gcaaagacct gcccacctc ctttcatccc actgtgaacc	4980
attgaaatac atatatatca	5000

<210> 5

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 5

gttttcgtcg ttttcgttc ggagatc

27

<210> 6

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 6

gctctcgctc tcgctattac tcgct

25

<210> 7

<211> 23

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 7

tgtgtatgcg cgttttttcg ttc

23

<210> 8

<211> 23

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 8

acctatatat ccgccgctcc gtc

23

<210> 9

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 9

cggcgttggg tatgtttagt agtc

24

<210> 10

<211> 29

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 10

aattacgaat aaaaaaaaca aaaacgctc

29

<210> 11

<211> 28

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 11

tgacggtttt ttgtttattc ggttattc

28

<210> 12

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 12

cgaacgcaaa cgtacctacg c

21

<210> 13

<211> 26

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 13

ggttaagttt ttttttyggy gtagtt

26

<210> 14

<211> 26

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 14

tactccctct acctcccrac tctctc

26

<210> 15

<211> 28

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 15

ttgtggygta gaggattatt agtttggt

28

<210> 16

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 16

ctaaaaacrc aaccatccc tc

22

<210> 17

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 17

ggaattttat ttgaaattt ttttggt

27

<210> 18

<211> 33

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 18

ccccacttca aataaaatac tattaaaaaa aac

33

<210> 19

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> forward primer

<400> 19

tagtgayggt tttttgttta ttyggttatt

30

<210> 20

<211> 26

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 20

taaacrtaaa aacaacaacc cracct

26

<210> 21

<211> 5000

<212> DNA

<213> unknown

<220>

<223> bisulfite sequencing of DBC1

<400> 21

ggttttttatt tgaagttggt tgattayggt gtttttagatt gatttttagaa ttgtattatt	60
agtagggtag ttgttgttta ttaatagtta tggaagtaga ttttagttgg gggatgatgg	120
ggaaataaag agaaagatag ggaygaataa aggaaggaat ggggtataga tagaaagaga	180
gagagagaaa agaaagaaag gaggagaggt aagagatagt gatttgggggt tttatatygy	240
ggtgggtggg agaaggagtg tgtgtggtgg gygtattttt tygtggttag aattaaagtt	300
agaattgatt tggggaattt gtgtttaaga tttgaatttg gattagaagt taagggaag	360
agaaagttgt ttaagaaaaa agggagaaat ttttattagg ygaaaataga aatygttgat	420
tgggtttgtg gttggagagt tgttygtggt gtlgattttt ttttattggg attttagtga	480

aggttgagaa	gttttgtatt	ggttgttttt	tttttttttt	tttttttttt	ttagttttga	540
ttttttgaga	tttaggatta	ttttggttag	ttygatgttt	tttttttttt	tttttttttt	600
ttttttgtyg	attaaataat	ttttttygag	tttttagttt	attattttaa	tatttttttt	660
ttattttgtt	ttaagatttt	ttttttttta	attagtttat	tggtttttag	attgtttttag	720
gtttttttgg	tggttatatt	ttttttttat	tattttttga	attaaaaaat	aaataaaaaa	780
tatataatgg	taattataaa	agtagataat	atgtattgag	tatttattag	gtgttaggga	840
gtagtttaag	tgtttttgta	tatattaatt	tatgagtagt	ttaagtgttt	ttgtatatat	900
taatttatta	taattttata	ttaattttat	tagatgggta	gatatattat	tattttatta	960
aatagataag	gaattgaggt	ttaaggggta	agtgatttta	ttaagattag	atagttatag	1020
gattttaatt	tttttggagt	ttgtattttt	attgaatttg	gtttttttat	atattttaat	1080
attttttttt	atgatttttt	gtttttttat	ttggtagttt	taatgttttt	tatttttgtt	1140
taatttttag	gggattaggg	atttgtattg	ttgatttggt	ttaaattaga	agggaaagtaa	1200
agtaaataaa	tatattaaat	gtgygttgtg	tgggaattat	tataygaggg	ttttattttt	1260
tgtttttaga	agaggtttta	tgtagtagt	tttagtttgt	atttaggttg	attgtagagt	1320
attttgtttt	ttatttttat	gttttagttt	ttgtattttt	gttttttttt	ygtttttggt	1380
ggtttttaga	gaatttygtg	tttttttagt	tttttttttt	tatattttgt	ttaygtagag	1440
aagtttttgt	tttatttttg	gaggttaygt	gggttttygt	ttatatatyg	agagaaataa	1500
atagtgttaa	atatttatag	agagaygygt	agatataaay	ggatttatay	gggtaatttt	1560
ygagataaaa	tttatatttg	atggatttay	gyggytggtg	aaatatttgt	ygtttttagaa	1620
atatttaggt	attygygata	tatatagtat	agttaygttt	aagggtatta	ggatttyggg	1680
tttgygygta	tgygyggttt	ttttggatgt	tygtgygtat	agatataata	ttttataygt	1740
tttagattta	ygaaattttt	tayggtttag	tttttagttta	ttygggtygt	tttttttytg	1800
aggyggtttt	tygttttttt	ttttttygtt	tttttttttt	tttygtttta	agatgtataa	1860
aatattttty	ggaagtaatt	tyggygttta	gttttttttt	tttygttttt	yggtygtygt	1920
ttttttattt	atttttyggy	gtygtygggt	aagttttttt	ttyggygtag	ttyggttttt	1980
gtygtttttt	gttyggagat	ygyggygtat	ttggattttt	ttttttatty	gttagtygtt	2040
tygttttygg	attttayggt	tgtaaattga	tttgggygyg	ggggaggagg	agagygtagg	2100
ygagygaatt	ygygagagag	ggagagagyg	agygagtaat	agygagagyg	agagygagag	2160
agtygggagg	tagagggagt	agtgatyggt	tttyggagty	gggatttatg	tttgttttyg	2220
ggattagyga	aggggatttt	ayggttgagt	atgagttagg	ttgttaggag	ttaggtattt	2280
ttaygtttgt	agttttygyg	tygtgttygg	aatgygagtt	gtaygtaggg	tttttttaag	2340
tttttatyga	gtygaataaa	aagygttttt	tygtagtttt	tygttaaaga	yggatattga	2400
tttttaggtaa	ggyggygtyg	ggtgtagygt	ttygtagttt	ygttgttttt	ggatttygggt	2460
tygggtygta	ttyggggygt	tttygygttt	ttttgttttt	ttttttatyg	gtatttttgt	2520
tygtttttta	tttggtyggt	tygtyggttt	taagtttttt	ttagtttttag	ggaggggggt	2580
tttgtgtttg	gggttttaaag	ggttaattgy	gggtttgagt	gagtgggygtg	tgtgttttyg	2640
ygygttttyg	aygtgtgtat	tatggtggga	atttgatgtg	gtgttagtgt	gtttgygtgt	2700
gyggygtygt	ttgygtttga	tgygtgtgtt	ygtgggtgtg	gtgtgtgtty	gtgtgtgtaa	2760
gggaggggtg	aagagagaga	ggttttataa	tttatttayg	gygygatgtg	tgtgtgtatg	2820
tttgtaygta	tgtgtttgta	tgtgtgtttt	ygtgtgtttt	tttaattagg	tttttttagt	2880
ttatayggaa	tgggattttt	attataggat	taygtagtta	tygggaaatt	ygttgtggat	2940
ttttttttgg	ggttttgggt	ttggggtttg	gggaggatta	tggggttgta	gatgggtattt	3000
tatttagttt	aatgttggta	ygtttgaagg	aaaatttttt	taaayggtgg	aattttgtta	3060
tattgggatt	tatagttaa	tatgaaagag	atatgggttaa	tttygaggt	aaatgagayg	3120

ttgttatttt aaattttata ttgggtagat ttttaagattt tgatgggaat ttggagatat	3180
tggatagtgg gtgatagaga aagggggaag ttagygggtgg gtttttttatt tggggtttgg	3240
aaagttttggg atagggtattt attttgtatt ttygtttgta attaatagag ttttttyggt	3300
ttttgttgggt tttggggagg atttggtaag tttgtatgga ttttttttag gggaaaggag	3360
aaagygtttt yggggatttg tttattttatt atagtgttaa agggtttttag aggaaatttt	3420
atttgggggyg gttgtggatg atatggaagg agatggatgg ggtatttttt taagatagat	3480
tygttttttt ttttttattt taggygggga agtttttaga gagttttttt ttaaataatgt	3540
ttttttatgg tttttttgga gttaggggga tattgagaga aggtagagag gtggagaggg	3600
agagagagag agtaagagy agagagaggg agatagagag agagagtgtt ttagtattga	3660
gggagattta taatttgaaa aggggtttgt agtgtggaat ttatgataga atgtggtagt	3720
aattgattta aattgttgyt ggtttgtatt tygygttttt tatttggttt taaaatattg	3780
ttaagggtag gggggyggtg gaggaatttt agttaggaag gtagtttggg ttaaggtttt	3840
tttttttttt ttttttattt tttgggaggt ttttaggta ggttttttgg ttattttggt	3900
ttggtattgt tgggttttggg ttttgggggt agttattgat ttgattttta gttgtttttt	3960
aaaggtttgt tttatttagt aaaaatgttg agttttattg ttgttagtat ggttttttaga	4020
ttyggtagtt gttatttttt taaggtaagy ggtagtygtt ttgttttttag gtagggaggt	4080
taggagaaga taagggttgt gaygttggga tatagttttt tgttttagttt agtayggagg	4140
ggygtttgaa aagttttttt aggggaaaaa agtagaaata tatttggttt aaaaaatgta	4200
tatatatatt ttaggaagat atatatatat atatatatat taattatata tatatatata	4260
tatatatatg tgtttatatt ttggggagag ataaaagtaa atatgtattt gtaggaattt	4320
gttttagtgg gtgggtttta tttgtaggta tttgtagata tattattttt tgttttagagg	4380
ttgatatttt aggttgaagt ttttatatag ttatagagaa ttttttttag gaaatttatg	4440
ttagggtaga gttttttgga ttattttggg taggggttat tagggttaag gaggagattt	4500
atttttggga attgttttat tttttttttt ttttaattta tagaygatyg aaattggaag	4560
gaatattaaa gagtagaaag gtaggatttt gtggttttaa gagggaatga gaatttttta	4620
atatttagta gtgggttagt ggtatgttta ggattagaat ttaggtttat taattagtta	4680
gattaatatt ttttttattt tttttagtaa tatatatattt aggattgtat attgttttta	4740
tttttatttt gttaatttgt tattatgatt tttattaaga taatygtttg ttttttttta	4800
ttaaatttta tatttttaga gatgtatttt agggtttttt tatttggaaa tatggttttg	4860
aagagaaaag atttaatgtt ttaattatta ttttygaaag atatatatat atatatatat	4920
atatatatat atatatatat atatatatat atatataygg tgggtgggggg aggattgaga	4980
gagagataga gagagaatat	5000

<210> 22

<211> 5000

<212> DNA

<213> unknown

<220>

<223> bisulfite sequencing of PDE8B

<400> 22

agaataattt tgaagtatta ttttattttt agaatttttt ttgtagggat gtttgagggtt	60
tggttaattt ttttttttgt ttaagtttgt ttttttttat tttttttttt tatttttttt	120

tataaatgtt	gattataaga	gtatTTTTTT	aaaagTTTTT	ttttgtttgt	taaatattat	180
tttagaat	gttttagga	ggatttaatt	tgtgtagaaa	ttttatgagt	aatttgtttg	240
tttaltaaaa	aatatagtal	agattTTTTT	taggttagtt	ggagatggag	tttttttgta	300
ttaaaaaaag	agagttaa	tgagaagaga	agtaaaggta	gaagaataag	gttagatttt	360
ttttgtataa	ttgaatttgg	gattgggaat	gataTTTTgt	tttttatga	aatttagaaa	420
ttgttttttg	aagtttttat	ttagttatat	ttaagagtgg	tttaggaaga	aaaaggaaaa	480
taagaatgaa	aaaaaaataa	aaaataaatt	ttaaaattgg	atattTTTTT	gtgttttgta	540
ttaagttttt	atgttatigt	ttttgttygt	ataagtaatt	ttagataaaa	ttttttttta	600
gattattttaa	tttattTTTT	ygtgttattg	tgaaaatygg	gtaggaatta	ttgygggaat	660
tagtgattga	atgggtagtg	gtgttttygt	gttgtaattt	agagtttata	agggaaggat	720
gaatagtagt	tattttttta	aaggatattt	tttttttttt	tagtatagtt	tagtttgtgt	780
atgtttttatt	aaggagaatg	agggaagggt	ttgttgattg	tttagtttag	agtgtgagga	840
atagtagttg	atatgggygg	ttggayggga	tagaaattag	tatgaatatt	tagtgataatt	900
taaggaagag	gtgaaaatgg	gggagaaagt	taagaattat	tagatagttt	ttttttgttt	960
ttgttttgga	ttttagggga	aygtatgtgt	ttaagggtgt	tttttttygt	agggtttttt	1020
atttttttgt	ataaatTTTT	aaaygatgag	tagatatgga	atgggttttt	tttgaagatt	1080
gggttattat	ttaatttagt	tttyggagta	ggyggtgggg	ttgggggaag	aggayggaat	1140
tatgaggttt	ttttattatt	tttygggtgt	gttgagaggt	aagtaa	ggtgggtggg	1200
tttgggttgt	agggtttttg	ttatttyggg	agggtttttt	tggtgttttag	ttttgggatg	1260
tgtgaaaatg	tgttggtgaa	aagygagagg	tttatatagt	tttttagggg	aagaggggtt	1320
ggggygttgg	gggyggygtg	gggatgagtg	tagaagagay	gaggtttttg	gatagyggag	1380
gaggagggga	gggygtygag	gygyggtgtt	agttgttyyg	tataggggtt	tygyggygga	1440
gtygagtygy	gggtaygttt	tgttttgtyg	ggagagtttt	gggagygggy	ggaggggygg	1500
agggygtag	tggggtttyg	gyggttyggg	tygyggagty	ggggtatttg	aggaggaagg	1560
agggtgggag	ygagggaggg	aggggayggg	ygtagatyga	aagtggggaa	agaaggtgta	1620
ggtaggyggg	taggygggyg	ggygttttgg	tttagggtyg	ygggtgyggg	agttyggyga	1680
ggtygagttg	ggyggygggy	gggtygygt	ygagggagga	ggggaagggy	gaggygyggg	1740
gagygtgttt	ggggygttyg	ggyggggagg	gtggyggtyg	ttggtgygyg	yggggygttg	1800
tgtatgygyg	tttttttygt	yggggaggaa	gatggtttta	aagggaaa	tggggtgayg	1860
ygygyggttt	tyggaggtty	ggyggggggg	atygyggtta	gttygaygga	gyggyggata	1920
tataggttyg	ggggygygta	gttygggygt	ygtgyggtyg	gtttttttat	tgtaggtggt	1980
agygggttyg	ttgggttttyg	gyggttyggg	gygygggygg	gygygygggg	gagttyggty	2040
gagggatggg	ttgygttttt	agtatttatg	tttygtagag	ygygtgatt	tattgttyggg	2100
attyggayga	gttaggttyg	tttygttaga	ttattagygt	gtygtagggt	tyggyggtat	2160
ttttgttygg	tttttttygt	tagatygayg	tygygaygt	tatttttttyg	agtygygygt	2220
ygggattttt	tagygtagtt	ygygttygta	gggttygtat	yagttgggt	agyggtagta	2280
gygygggttt	ygtagttttt	gtygygatta	ttagtagggg	tyggaggygt	tattgttgta	2340
gtagygttyga	ggtygagatt	tagatttgtt	atattagygt	gaaggtaa	gttttygygt	2400
ggtataygty	gtgggggttyg	ttygttttygt	ygygggggtt	ygtaygggta	gggggttttyg	2460
gyggagtggg	gtgatytgta	ggyggttggg	ttggagaggt	tgttattaag	gaggagttta	2520
ttttttattt	gtggagatga	tgggagttta	ggaaatgtgg	ttagaaaaag	gtttttggag	2580
gggttttgga	agygttttta	gttggttttg	ggggattggg	yggggaaggg	agygtagaag	2640
gaagtaggtg	ggttggtttg	tttttttttg	agggtaggaa	ggttgtggtt	tggtttatgt	2700
aggaagaggg	gtggggatta	ttgagagtat	tyggtgggtta	gttttgttga	atgaaatttg	2760

agtattgagt	tggatttgyg	tgtttttag	gtgattggtg	tagttgtagt	attaggatag	2820
atagtgtttt	atatttlygat	ttttatttgg	gattattagt	taggttggag	ttttagtata	2880
ggaatygagy	gtagggattt	gtgaatgaat	gagtgttygt	gttttaagag	atgtgggaay	2940
ggagtagagt	ggaatttggt	gtttgttatt	gtaaygtttt	tttgggttgg	ttgtatttta	3000
gatagaattg	agagaatygg	gttatgagtt	yggagtgtta	gtagagttaa	ygtgagggga	3060
ygtggttttt	agtgtagtat	agttgtttga	ggatgatttt	gtatatataa	ttgatttttt	3120
tagagagtgg	gattttgagg	aagtggaaaa	aattgttttag	atggttaaag	tagtygttaa	3180
atattttatt	tttaaagata	gaagaaaaat	aattatttaa	atagtgtttt	tttgtatgtt	3240
tttaaagtat	ygttaaattt	aagagggttt	ttattgtgta	aatttgggta	ttgggttttt	3300
ttttttttta	glaaataaga	taataatggg	atattttatt	gtatagagag	aaaaaatat	3360
ttttaatgtt	agatagaatt	atagttttta	tttggttaat	aggttattaa	gaattatttt	3420
atggattatt	tgttaaagat	atatttgtat	ttttaatagt	taaaaatttg	gtttttattg	3480
gatgaaggta	gtttatagtg	gaggagtggg	gagaaggata	atatgttttg	gttttaattt	3540
ggaagtttaa	aagtttttta	atgaatttat	ttttttttta	atagtatttg	attgtttaat	3600
atgaagtttg	attgatgttt	gtttgtgggt	gtagtgtttt	tttggtagta	attataatta	3660
ttattatagt	aaaaatatyg	tttattgagt	atttattatg	tgttaggagt	aagttttttt	3720
ttttaattat	tgaatgttaa	tagtgtgatt	ttagtatagt	atgtttgaag	attagagttt	3780
aggatttatg	atagtataaa	tttattagtt	gtttatttygt	tatagaggta	tgtgttgaay	3840
gttatatttt	gtttttgtta	agtttttttt	tttttttttt	ttttgtttat	ataaagttag	3900
ttttaggagt	aatttttagg	gatgaaaatg	ttaaatttgg	tgaaaatatt	aagttgggat	3960
attattagta	aagattattt	ttttgtttga	yggttgaaga	tttgaagtag	tagtttaaaa	4020
ttgtgatagt	ttatgaattt	tgtgatattt	tttttgggtg	tttttagagaa	attgtgaatt	4080
tttgtttttt	agaatattta	taatttttagt	ttagtatttg	gtaatttttag	ttattttatg	4140
tttgtttagt	agaagaaaga	atattgaatg	aattttatttt	gtatatatttt	aataatttttt	4200
ttaagaggtt	gttttagagat	taaatgaagt	aaaaattgaa	gggataatga	gttttaattta	4260
ttagtagttt	gtataaaattt	gtattaattt	tattgtttatt	tggtttaagt	attaaaagggt	4320
ttgatttggg	taggagttta	atttatttttg	ttttattaag	aagattttta	aataagagtt	4380
taattttatt	taattttatta	ttgggaatgt	tggaaatgaa	atttttgggt	tattgattta	4440
atattatttt	gtatttgttg	gatttttagaa	agtatatatt	tgaagtgaag	tttgagatta	4500
gagttattta	tgtaaatttt	atagaattat	tatttatagaa	ttgttttaaat	atattttaata	4560
gtattttttt	aggtttgtga	ttygggtgtg	tattgttttt	ttttaatygt	aaagttttata	4620
tgttttgtgt	ttttttgttg	ttgagataat	tttataaaaa	ttttatatatt	atttttttgt	4680
agattaagta	tttttttttt	gtygtaagag	tttgagatag	ttgttaggta	ygtgggtggtg	4740
ttttattttt	ttttaaagta	tatagggtgga	aaaataaaaat	ttttattatt	tggttttgtt	4800
tatagtgggtg	gaagggttga	atagttttta	tttttttttt	ttggttattt	tatatttaatt	4860
atgaagtgtg	tttttattat	ttatttgggt	tttgggtattt	tttagagtgt	aaaaatgtgt	4920
gtttgatatt	tttttttttt	tttttttagta	ataattttatt	ttattaagtt	tttagaatga	4980
tgaggattta	tgatgttaaa					5000

<210> 23

<211> 5000

<212> DNA

<213> unknown

<220>

<223> bisulfite sequencing of PTPRR

<400> 23

aagaaaaata gatttattgt aagtgggata taattat tttttaattt ttagttttgt	60
agtat tttta gtaatagatg ttagatgaga agagt ttttaagttt tatagaatgt	120
taaataaatt attttaaagg ttgatttagt aagaatttta aagagttaat tgttagtatt	180
gaattttgtt aattattatt tttatttatt tatttttgag tatttatttt gtatgaggta	240
ttgttttagg gagttgggat atattaataa agttattaaa gttttttaat attggagttt	300
aaattttgtt ttgygggggg gagtagggaa atagatatta aataatagat tttataagta	360
attat tttgg tttgttagaa agtgataygg gaaaagtaaa ttggaggata gtgaattagg	420
aataggagaa gaggtttagt ttttagagtgg ttgggatga aatgatagtg ttatagaaat	480
ggagtgtgtt ataygtatgg gggagtaggg ggtggagtay gttgttagag aggggttaga	540
tatggagata tgtttttatt ttttagtagag aaggtttgtt aagatattaa aagtatattt	600
tattgttttt tttttttatt tgttggagtg ttttttggtt ttgtttttta gagttgaaga	660
tgatataaat tataaaagaa ataaatggta tygtttgggt tttttgattt tataaggttt	720
tatttaattt aagttttggg ggatagttta ttttttatta gttgttttaa tttatagagg	780
atggagaaag aaagtattga atgagatgtg tagtttaatt taatgggtat ttgttagttt	840
taattat tttg gttaggataa ttttatttaa gttaatggaa tataaaattt agtagttttt	900
atggagattt taatgtgttg tagaataaat tatagataaa tgaattgttt gaaagaataa	960
tatgaggtay ggttaaataa gtgttgtgga agagaaagat tattgtaatt tagagttagt	1020
tagagttagg gtttttttga aaagtgagat taatattata ttttygaaaa ttagtgttgt	1080
ggtggtgtaa gtggaggaaa atgggaaaga ggtaatagtg tttataaaga tatagaggta	1140
gaaagggtag aggttttggg atagttaaaa gagaagttta gttgagggat tttttgattt	1200
gattagtagt aattagttat gattaataag gttttttata ttttaaagat ttagatggag	1260
ggataaaaaa ttatttaatg gtagattgtg gtagtttttt tagagatata gagttgggty	1320
ggatgagttt aggtattgay gtgatttatt attttttatt ttaaagagta aaagggaat	1380
taaagttaat tttttttayg aaataaaaag gtgttttttt gtgttttaatt tatatggata	1440
tattttatta gtttaaaagt atttttttat ttttttttgt tattgtgagg atttgagtta	1500
gaagaaagt taaatatagt tattgagttg gaaagagtgg aaagagaagt aaagaggggg	1560
aagttgtagg aaggaygaag ttatttttaa gatatatggg tattgtttat attaagtaag	1620
ttgttttggg aaygttttt tyagtagtt agaattttta gtagtggag atatttttat	1680
ttttgtaggy gagttttggg aagttggtta atttgtaaat gttaattttt agtagtgagt	1740
tyggtttayg tgtaaattaa gatttgggga aagagtaggg tgggtggtat gggtgataat	1800
gttattagtt tttttttttg atttttgttg tygtgttttt atttattttt atttagttat	1860
attttatttt yggatttgtg atggaygttg ggttttttagt aattatagta agtgtttttt	1920
tygtattttt ttttttttta tttttatttt tatttttaatt tattatttta gygatggagt	1980
ttattttgtt ttaagtygty gttaagatty ggagaagygg aattttattt tgaatttttt	2040
ttgttttytg agggtyggyg ttgggtatgt ttagtagtyg yggygttgtt gttgggttgt	2100
tgggttgggy yggagtttat tttgttygtt tygttttggg ttttgggygt ttagaaggtt	2160
aggtatttgt ygtttttgag ygtttttgtt ttttttatty gtaatttttt attgtttttt	2220
tttttttttt ttttttaggga ggttgaagtt ggtgttgggt tttgttyggy ttatagattg	2280
attgttttgt aaatttttagt ygaggatttg aatttyggag attagaagat ttttggyggt	2340
ggtttttttt aatagtattt tatttgaagt ggggttygttg tggagttttt tttttatttt	2400

ttaatgtaaa	tattatgygg	agagtagttt	gtttttttgy	gttgtgtttg	ttttttaatt	2460
tttaygttgt	aggtaagggg	ttgttaggtt	tagagtygga	gttgtgtatg	agatgggaaa	2520
ttgtatatgt	ttaaggattt	taggaaaagt	ttgttttgyg	aagaaagttt	ttttaaaaag	2580
gtaaaatagg	atagtatttg	atagggaagg	ggtgagggag	tygtgtattt	gttggaaaat	2640
tgaggtygaa	aatttaattt	aaaattagtt	tttgattttt	ttttatttta	taygaaaata	2700
gtgaatat	ttaatatgaa	tataggtttg	tttttttttt	ygtttttttt	tygttttagat	2760
tttttgtttt	tgtttttagg	ttatgtat	aattgtta	tttttaggag	agggataaga	2820
tattttgtta	gatgtaattt	tttttattgt	agyggttatt	atatttataa	ggttttttgg	2880
tttagygagy	gtttatagga	aggtatttgt	tgtaatttga	tggattatat	tttygtttaa	2940
aagatygaaa	tatatggttt	atattagtg	tgttgtatta	ggtttttttg	gtttttgttt	3000
ttgttattyg	aattttttta	gttaataaga	ggaagaaaag	gttttaata	gaattttttt	3060
gtttttttta	gtatygttgt	tagygttygt	tggtatatta	aaaaaaaaaa	aaaaaaaaaa	3120
aaaaaaaaaa	ataattatag	ttttaaagtt	gataattttg	ggttaggtat	tgtttttygg	3180
atagatttga	taaggtgtaa	ttaagagtaa	tagtgagatt	gtttttta	ataaatagat	3240
ttgaggtatt	agaattaata	ttaagtttyg	tgaggaagta	aattttggga	agtatttgag	3300
agatattata	tgtggtgttt	ttgttttttg	tatatatagt	atttttattt	aatgtagata	3360
gatttgtag	gttgaatttt	ttattattgt	tatatatata	tgaattaaaa	taaaatatgg	3420
tagggagatt	ttagaaattt	tattgtgata	gtagttgttt	atgtagtagt	tttgtaataa	3480
ttagagayga	ggtatttttt	ttgagtgtgt	tttttattta	attatatata	tttattttatt	3540
ttttaagta	atatttgttg	agtgtatatt	atgttttagg	ggtaatgagt	aaaaataatt	3600
gttttgaaat	tataattttt	gtagtatttt	ttttaaaaga	gtgggtgaat	tttatttttt	3660
gtgtataata	gtaggagtga	aatatgggtat	ttttttattt	tagttaaygt	tattatttta	3720
atgtattatg	aattttttga	gtaaataatg	tataggatta	ttaaagttat	tattaaatat	3780
atatgttaat	tgttataatt	atgatgttat	attgtggagt	ttttaatagt	tttttggtat	3840
attttgagaa	gtagaaaata	gttatgattt	gattatttaa	ttatttgtaa	atagttgtag	3900
tgaattattt	ygttattata	tataattttt	taatgttgaa	atgtgggatg	aaaatatata	3960
tattgggttg	agttttattt	atagtattgt	ttaataatag	attgatataa	atattttatta	4020
tagaaaaatt	ttaattttta	ttaaggtagt	aatgatttag	ttggtttggt	aataatatta	4080
gtgtagttat	ttttttaaaa	ttaatatata	aaaaagttta	aagattatat	ttgatataatt	4140
ttgagtaatt	atatttttaa	agttataaat	aaattgaagt	atgtgaaaaa	tatgttttga	4200
tttattgtag	atgaatatty	gggatgagaa	aaatgaggat	ttttgtttat	tagatgagaa	4260
atltagaagt	ttgtagtttt	agattttatt	tggagttttg	ttaaagggtta	tattatttaa	4320
gttaatttaa	tttattttta	ttttaatttt	ttaatttgta	aaataaagat	aaaaagtaag	4380
attaattaat	taattttta	ttaataagaa	aatgtattta	aggatatatt	tatttttta	4440
ttgtaagata	ttatttat	tatttatatt	taatataagta	aaatatattg	gtgtttttatt	4500
atagtagatt	gtaagtttaa	tattatagtt	tttttgttaa	ttttatttta	aatgtatttt	4560
aattttaaat	agtaatttgt	gggttataag	ttgttatttag	attaaaattt	attatagtta	4620
tttaataata	ttgttaggggt	tttttattag	aattaaaata	aatatagttt	tttggtttta	4680
gtttttatat	atltggagat	taagaaaata	agtggatggg	atgataaaga	ttaagaaatt	4740
aagatattaa	tttttatttg	ttgaagggtgt	gagtttgta	tttttatgga	agattttttt	4800
tttagaatag	aggttgattt	tataaagaag	ggaaatgaat	tttatatatt	taggtttttt	4860
taattgtaaa	gttaattgat	ttatttttgt	taygttttagg	gtattagtaa	ttgttttatg	4920
ttgggtggaat	tgatgatatt	ttataatgtt	ttagagatgg	gaggaatgtg	ttaaygggat	4980
gtaagtgttt	tttttagtta					5000

<210> 24
 <211> 5000
 <212> DNA
 <213> unknown
 <220>
 <223> bisulfite sequencing of ZNF582

<400> 24

gaygattttg aatgattttt gtttttttagt atttatatatt ttgtgtagtt tttattttatt	60
tagattttata gttgattttg tgattaagag tataatggtg tatgatttta gaggttttgg	120
ttagagtttag aagtggttat tttattattt tttaaatttt tttttggtag attaatgaat	180
gtgagaaagt aaaaatggta tagaagaaag ttagtttgag agatggttgg ttttgtattt	240
gttttggtttt tttttttttt tttttttata agtaaatttt gaygtatgta tatatagata	300
tatttaatat agtgggatgt taaagggaaa ttagagttat tygttttttt ttaagattag	360
agaatatagg aaagatgatg atttttttgta tttatttttt ttttttgaat tygtaattat	420
gttttgaatt ataaataagg ttaagtagga taaattttata attgtttttt taattgttyg	480
tttataagtg tgaaatttaa ttatttttgt tgaagtgtgt ttttaatat agtaattagt	540
aataattaat ttttgagttt tgttttatatt attaaattat tttatttgat ttttaggata	600
aagttgtaag tttagtatta tttttttttt tttatggata aaaaaaaaaa aataaaaataa	660
aatyagata ggtaygaaga aattaataaa tggttgaaat gttatttgaa tttatatattg	720
tttaatttta aaagtgtgtt ttttattata ttatygtatt tataaggaaa atgtagtttt	780
tatttttttt tgaagaatgt gtaaagaggt aatatggtgt gtttttgaaa agtatatttt	840
gtagaaagaa agtatttagtt ttagttatat tagtattttt atttagtagt agtagtatta	900
ttttatatat tagttatttt tttttaataa tttaatgaat tagatgttat aattattttt	960
atttttaaat gtggagatyg aggtatatatt ttaagattgg agtttaggta ttttggtttt	1020
agtttttagag atggttaagg gtttataatt ttaattattt attatattat agagtttatt	1080
aggtttgagg gaaataggat taaattaaaa gagttattta ggatttttagt ttttatttaa	1140
ggataaattg ttttatttyg gatagggaga gttttygtat tttgagattt agtataatag	1200
gttttgatyg gtatttggta ttyggatttt taattatatt ggattatatt ggttygggat	1260
gtgtaaagtt tagggttttt tataattgat gatattaaag tygtttaaaa ataagagaga	1320
attaataatt atttayggyg gtttgatatt tgtttaagag atgtygtttt ataaaatttt	1380
tttatatttt tataaygttt ttattttgyg ttttttttta taatttatat ttaatttatt	1440
atagatgtaa tgtttaaaat tagttattag ataaattttt aygtttttta attttaaggt	1500
tttttygaaa ttttttggta aaattgttgt tttyggaaa tgggaaygta ayggatgagg	1560
taatttttta tagtygtata tagttgtgta tttatygtta aayggtttta gttatatatt	1620
taaygattta ygyggagtta gaagttatta ttatatattg ttaaaattay gtatatatag	1680
tgayggtttt ttgtttatty ggttattygt ttataatttt tygttagaga attataygta	1740
gatagtatat ttagtattat agatttttagg aagtaattta gggattygaa tataygaata	1800
gtattttttt gygtattgyg taggtaygtt tgygttyggt ttattttgaa atatygygag	1860
attyggtttt aaggtygggt tgttgttttt aygtttaaag attatgtttt tyggaagata	1920
ttgyggygty ggttttatta tgggytagta tyggtgtgtt ttgtgygttt gygttatttt	1980
tyggttgygt ayggygaatt tatyggtaty gtgggtggaag ygygttttgg gttgtygggg	2040

gygyggtygy ggtggtat	ggattygagg aggyggtagg	tgagaggttt yggagttttt	2100
taggygtttt ggggttttagt	aggagttagt gtttgggtyg	gttgggtttt aggtttgaga	2160
agaaygtaga ygttttygtt	tatygttygtt ttgtggtttt	atyggtygtga gatttatatt	2220
ttygttygggtt ttygyggygt	gygtttttttt gygttttttt	tttgtttttt gttttatagt	2280
ttaggtgtat ggattttttt	ggtgggtgyg taggggtttt	ygattttttt aaattgygga	2340
tgttttgtat ttattgttat	gygtgttttt tttttttttt	aatttgagag gaaattttgt	2400
tttatgaggt ttttagagag	ttataagatt ttagaagatt	tagaatygtt agtttagaaa	2460
aatttatatt tgggaatatt	ttatatgttt aaattttatg	tttagtaatg gggaaatatt	2520
tgagtggatt ataggttatt	ttttgtaaat aggatatygt	gtagttaata taaataatgt	2580
ttataaaagt ggttataata	aggaaaagtt gtttattata	ttatattaag taatatttat	2640
aattatttta tttataygtt	atttagaatt aaatgtttgt	aatgtagtag gtattttata	2700
tattttttta tagagtattt	tttgtttaat agtgagttta	agaattgggt aaatgataat	2760
attgygaata tttgggtgtt	ttttttttta atttttttgt	tttgttttgt ttttagtttg	2820
tgtgttagtg agtttgattt	ttttttgttg aatgttttta	aaggatttag tagttaatat	2880
ttttgtttgt tagtttttga	tagttatttt tgatagttaa	ttggtatttt attatatggt	2940
tgtgttaaaa atgattta	at tttttggtta tttgtggatt	tgtttattta ygtattaatt	3000
tttagttttt ttatttagta	aatattattg gatatttagt	tttgtgtatt gttgtgtttt	3060
tatggaagga tatatttatg	tgttgataat ggagtattgg	gygtgtttgt tgtaatttgt	3120
tttttattgt tttttttaat	tttattttat ttgttgatgt	aaggatatgt ttatgaagtg	3180
gtatgtataa agtttttagt	tgggtttagt agttttttgt	atatttggyg gttgggaaaa	3240
gagttaggta gatttttaaa	ggtgttatat ttgtttagg	agagagttaa atggttttagt	3300
tttggaagg ttttatttta	ggttgggggt atgtaaatga	tgtaggtttt ttatgttttt	3360
tggtttgagg gaagtttttt	ttgtttttga ggtaatatgt	gggttttagt tattagaata	3420
gttttttagta tttttgtttt	agatttgtat ttgtagtaaa	atagaattat tggatgttta	3480
ggggaaatgg gagggaaagg	altattgggt tttttttgtt	ttgtagtagt taaagtgggt	3540
tttttgggggt tgggtgagga	ttttttttgt tttttttttt	ttttattttt ttggtgggta	3600
gagggttaagt aggtggggat	ttgtaatttt gtatttttagg	aattgtgagg taagttagt	3660
tttttatgtt tgtttttttt	tttttttagt ttatygttygt	aggattttgt ttttttttaa	3720
gagaggaatt agaaggagga	tttattagtt tttgaaattt	taaaagttaa gttttttgtg	3780
agtttttaaa ttttataaat	atttgttttt tttattttga	aattttttat ttgggtttta	3840
tttagaaatt tggtttttag	atttttttat tttagggaat	aaaaggatta ggtaggagtt	3900
ttttttttta ttgttttttt	ttttttgata aatgtttata	gatttatttt ttatagtatt	3960
ttgtattttt tgatggtttt	ygtttgttag gaggagaaat	ttattttttt gtatgaaatg	4020
agagtatttt ttgtaagaat	tgaagtttga agagatggaa	tgaatgttta ggagtaatta	4080
tatatagaaa agtaggggag	gtggtgttgg ttggtttttag	ttttagygtg tggatatagt	4140
ttttgttttg ggaatgatta	atgattggat atgtaattga	ggtttgggtt ggaatttatt	4200
aaaaatttga tgttagaatt	aaagttagt ttgaygttgg	atagagtatt tgaatttggg	4260
atatttttta ttagtttttt	tagtttaaga ggaagaaaag	tatagagttg aggatggtga	4320
gygatgtagt aagttagatg	attatttagg tgggttagtg	gttagggttt ggaaaagttt	4380
tagagatttg atttaattty	gggattttaa ataagaggat	gtttgagtta gttgttttat	4440
ttgatagaaa atttgtattt	taataaaagt tatttttatg	gtttttttta tgaagaaaaa	4500
tgtttgtgtt atgtttta	at ataagatga atttttat	ttt ttaagaaatt tttgat	4560
atgaaaattt tgtattta	ag atagaaaata tgtttt	tata attttaaaaa ataaa	4620
tggggaaaat ttattagaaa	tattttttgt tgttattgtt	at ttttaaaaag atagaagt	4680

taggttttat tttgagaatt tattgtatgt taagtataga gtgggtagtg tgttttatta	4740
tattgttttt taataataag gaaaatttta tttagtttga ttttaatttt tatttttagat	4800
ttgtatatag agtattgatt tgtagttaaa aggaatgttt gagaataatt tgattatttt	4860
gttttattta tttttatttt ttttgttatt ttttatattt agttttattt tttttgttta	4920
ataaaataat ttttttttly gtaaagattt gttttatttt tttttatttt attgtgaatt	4980
attgaaatat atatataatta	5000